Targeting cancer with reovirus. by Comins, Charles J.
  
 
 
 
Targeting Cancer with Reovirus 
 
 
Charles Comins 
 
 
 
Thesis submitted to the University of Surrey 
 
 
 
 
Microbial and Cellular Sciences, School of Biosciences,  
University of Surrey 
 
 
 
 2 
Abstract 
 
There has been increasing interest in oncolytic virotherapy for the treatment of cancer 
over the past decade. Reovirus is a ubiquitous double-stranded RNA virus that is 
oncolytic. It has been shown to selectively kill cancer cells in murine, and human 
models. The mechanism by which reovirus selectively targets and kills cancer cells is 
slowly being elucidated. Activation of the Ras pathway in transformed cells plays a 
part in the permissivity of cancer cells to reovirus, in part through the inability of Ras-
activated cells to phosphorylate cellular PKR. Our microarray analysis found 
increased expression of epidermal growth factor receptor (EGFR) in B16 mouse 
melanoma cells after exposure to reovirus. As EGFR is a component of the Ras 
pathway, we explored this increased expression and found that in certain cell lines 
there was an increase in EGFR expression after reovirus exposure both by PCR and 
western blot analysis. Data is presented looking at the effect of silencing EGFR on 
cell survival. Early human trials indicate that while reovirus is safe and capable of 
inducing cancer cell death, single agent activity is likely to be limited. Attention has 
now focused on combination strategies. We evaluated the combination of reovirus 
with rapamycin in the B16.F10 murine model of malignant melanoma based on 
potential mechanisms by which mTOR inhibitors might enhance viral oncolysis. 
These include cell cycle arrest, targeting of alternative signalling pathways, and 
suppression of the antiviral immune response. Rapamycin attenuated viral replication 
if given prior to or concomitantly with reovirus and similarly reduced reovirus-
induced apoptotic cell death. However, we found clear evidence of synergistic 
antitumour effects of the combination both in vitro and in vivo, which was sequence 
dependent only in the in vitro setting. Rapamycin showed no systemic 
immunomodulation and cell cycle effects of reovirus (increased G0/G1 fraction) were 
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unaffected by concomitant or sequential exposure of rapamycin. We also conducted a 
multicentre, phase 1 dose escalation study designed to assess the safety of combining 
reovirus with docetaxel chemotherapy in patients with advanced cancer. Patients 
received 75mg/m
2
 of docetaxel, day 1, and escalating doses of reovirus up to 3 x 10
10
 
TCID50, day 1-5, every 3 weeks. 25 patients were enrolled, with 23 completing at 
least one cycle and 16 suitable for response assessment. Dose-limiting toxicity of 
grade 4 neutropaenia was seen in one patient but the maximum tolerated dose was not 
reached. Antitumour activity was seen with one complete response and 3 partial 
responses. A disease control rate of 88% was observed. The combination of reovirus 
and docetaxel was concluded to be safe, with evidence of objective disease responses, 
and warrants further evaluation in a phase II study at a recommended schedule of 
75mg/m
2
 of docetaxel, 3 weekly and reovirus 3 x 10
10
 TCID50 day 1-5, every 3 weeks.  
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1.1 Cancer 
Cancer is a broad term used for any disease in which abnormal cells divide without 
control and may invade other tissues. Though there are over 100 distinct types of 
cancer, as well as different subtypes within specific organs, they all share a number of 
traits: production of growth signals, lack of response to antigrowth signals, evasion of 
apoptosis, ability to replicate without limit, angiogenesis, and the ability to invade 
tissue and metastasise
1
.  
1.2 Brief History of Cancer Treatment 
Up until the end of the 19
th
 century cancer treatment meant excision of the tumour by 
surgery. Though curative surgery was possible, and reported, the chances of success 
were largely dependent on the accessibility of the tumour and the speed with which it 
was discovered. Advances in surgical technique lagged behind discoveries in 
pathology and physiology at that time and it was only in the latter half of the 20
th
 
century that progress was made such that surgery remains a cornerstone of modern 
cancer treatment. 
 
The discovery of X-rays in 1895 by Wilhelm Roentgen, radioactivity by Henri 
Becquerel, and radium in 1898 by Marie Curie opened up a completely new modality 
for cancer treatment. Radiation was employed as an anticancer therapy remarkably 
quickly after it had been discovered, with the first report of X-rays to treat breast 
cancer appearing a few months after Roentgen’s original paper2. The first report of a 
cure from radium treatment was published in 1903 in a woman with cervical cancer. 
The science of radiation therapy developed rapidly in the first half of the 20
th
 century 
but the initial enthusiasm waned when it became clear that, for the majority of 
cancers, cure remained elusive and treatment morbidity was significant. Since then, 
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there have been significant technical advances allowing improved results and fewer 
side-effects, however impact on long-term survival has been small. 
 
Cytotoxic chemotherapy for the treatment of cancer began in the 1940s, initially with 
the use of nitrogen mustards and then in 1948 with the introduction of folic acid 
antagonists by Farber
3,4
. His work using aminopterin in acute leukaemia led to regular 
remissions and sparked a huge effort to discover other chemical compounds with 
anticancer properties. A large number of such chemicals have since been discovered 
and have proven effective in a variety of cancers. However, despite significant 
progress in the treatment of haematological malignancies with chemotherapy, their 
impact on solid tumours has been less dramatic and only the relatively rare germ cell 
tumours and choriocarcinomas can be cured by chemotherapy alone.  
 
Surgery, radiotherapy and chemotherapy remain the principle treatments for cancer 
and the combination of two, or all three, has become the gold standard for many of the 
common solid tumours. While this has undoubtedly led to improvements in survival 
there is still a significant need for new treatment modalities. 
 
The explosion in our knowledge of cancer molecular biology has led to the 
development of new, more ‘targeted’ agents. Antibodies that block specific cell 
receptors over-expressed in cancer cells, or small molecules that inhibit key enzymes 
in cellular signal transduction, have been designed and shown to be of clinical benefit. 
For example, trastuzumab (Herceptin), a monoclonal antibody of the HER2 receptor, 
is now the standard of care in combination with chemotherapy, both in the adjuvant 
and metastatic setting, for patients with breast tumours over-expressing HER2
5-7
. 
Erlotinib (Tarceva), a small molecule that targets the tyrosine kinase activity of the 
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epidermal growth factor receptor (EGFR) has proven beneficial in patients with non-
small cell lung cancer who have progressed on chemotherapy
8
. 
Many of the molecular targeted drugs now entering clinical practice have been paired 
with conventional cytotoxic agents or radiotherapy based on standard of care. 
However, further insights into the molecular biology of cancer are now allowing a 
more scientific rationale for combining different targeted agents. 
 
1.3 Oncolytic Virus therapy 
1.3.1 Brief History 
The concept of agents, unlike bacteria, that could pass through filters, was first 
reported in 1898 by Martinus Beijerinck regarding tobacco mosaic disease
9
. He 
defined the virus as a contagium vivium fluidum, but it was not until 1917, when the 
plaque assay was first introduced, that the particulate nature of viruses was 
ascertained
10
. Electron microscopic images of viruses were obtained in 1939 allowing 
their structure to be observed for the first time
11
. Our understanding of viruses grew 
considerably with the ability to grow viruses in cell culture in the 1950s
12
. Since then 
viruses have been studied in enormous depth: their genomes have been sequenced, 
their physical structures defined, and their methods of replication and pathogenetic 
strategies elucidated. More recently methods have been developed to genetically 
modify viruses to improve their capability as anticancer agents. 
 
It is likely that the use of viruses in the treatment of cancer was the result of the 
observation that clinical remission was occasionally seen in patients who contracted 
an infectious disease. These early reports were almost exclusively related to 
haematological malignancies, which are associated with significant immune 
 17 
suppression. As early as 1904 there were reports of the beneficial effects seen in 
patients with leukaemia who developed influenza
13
. Although there were no reports of 
complete cure, even at this early stage there was anticipation that viruses may hold the 
key to a novel treatment long before the advent of conventional chemotherapy. More 
recent clinical reports have described the regression of leukaemia, Hodgkin’s disease, 
and Burkitt’s lymphoma in association with measles infection14-18. From these reports 
investigators have deduced the following: occasionally, certain viruses can destroy 
cancer cells without causing undue harm to the patient, this is most often seen in 
patients with a suppressed immune system, and these virally-induced remissions are 
short-lived and incomplete
11
. 
 
Formal evaluation of viral therapy began in 1949 with a study looking at hepatitis in 
22 patients suffering from Hodgkin’s disease19. Of the 13 patients who developed 
hepatitis, 7 were reported to show improvement lasting over a month or more. With 
the hindsight of modern medical ethical standards this trial, like many others at the 
time, seems questionable: the study subjects were given multiple inoculations of 
hepatitis collected from patients with infectious hepatitis, and the death of study 
subjects from hepatitis was reported, though the number of patients dying not 
recorded. Another early trial used glandular fever serum in the treatment of acute 
leukaemia
20
. Five of the treated patients developed symptoms of glandular fever and 
three of these went into temporary remission. Encouragingly, side-effects were 
described as mild and no deaths recorded. 
 
Over the next twenty years a large number of different human pathogens were 
assessed in clinical trials. Early trials focused on West Nile virus, but limited 
responses and concerns regarding neurological side effects meant that its development 
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was dropped
21
. Attention then turned to adenoviruses and herpes viruses. 
Adenoviruses were initially viewed with enthusiasm having limited side-effects and 
dramatic responses after intra-tumoural injection. However, it became clear that 
adenoviral infection was rapidly cleared by the immune system, especially in those 
with pre-existing exposure to adenovirus
11
. This gave an early indication of one of the 
major barriers to successful oncolytic virotherapy.  
 
The final human viral pathogen to be assessed in any detail before enthusiasm for 
oncolytic therapy waned in the 1980s was the paramyxovirus mumps. In 1974, Asada 
et al. reported the results of a trial assessing the effect of non-attenuated mumps virus 
in a number of different tumour types
22
. Despite differences in the source of the 
mumps virus, quantity of virus administered, and delivery of virus, they reported that 
37 of the 90 patients treated showed regression of their tumour by more than 50%. 
Little in the way of toxicity was reported and responses were often seen within a few 
days of viral administration. Subsequent studies assessing mumps were less 
successful
11
. The lack of significant efficacy coupled with the risks of using non-
attenuated human pathogens led to a temporary hiatus in oncolytic virotherapy 
research.  
 
Methods to limit the pathogenicity of oncolytic viruses were attempted as early as the 
1950s. The concept of viral adaptation, whereby the oncolytic potential of a virus was 
enhanced by numerous passages in a given tumour, had been proven by Moore et 
al.
23
. They rightly assumed that viruses would develop mutations that would enhance 
replication in the cells in which they were propagated. However, it was not until the 
advent of recombinant DNA technology in the early 1990s that the prospect of 
altering the selectivity of viruses became possible. The first study to use this approach 
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was published in 1991 by Martuza et al. using a genetically modified Herpes Simplex 
virus (HSV)
24
. HSV mutants that lack thymidine kinase are only able to replicate in 
dividing cells. When these modified viruses were used in a nude mouse glioma model 
they caused tumour growth inhibition and improved survival. 
 
Since then a large number of human pathogens have been genetically modified to 
increase their specificity for cancer cells and enhance their oncolytic capability. Table 
1.1 lists some of the oncolytic viruses, both wild type and genetically modified, 
undergoing clinical development, their presumed mechanism of tumour selectivity 
and clinical efficacy. 
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Table 1.1 Oncolytic viruses in clinical development 
Virus 
Species 
Genetic 
Modification 
Mechanism of Tumour 
Targeting 
Phase Results References 
Adenovirus Yes 
Replicates in cells with tumour-
specific promoter-driven 
expression of E1A 
Phase III 
i.t. response 
enhanced by i.v. 
cisplatin 
No systemic 
efficacy 
45-49 
HSV1 Yes 
Only able to replicate in tumour 
cells 
Phase III 
i.t. admin response  
No systemic 
efficacy to date 
50-52 
Vaccinia 
virus 
Yes 
Only able to replicate in tumour 
cells 
Phase II 
Evidence of 
response when 
given i.t. and i.v. 
53-55 
Reovirus No 
Selectively replicates in Ras-
transformed cells 
Phase III 
Evidence of 
response when 
given i.t. and i.v. 
78-113 
Newcastle-
disease 
virus 
No ? Boosts immune response  Phase II 
PV701 strain has 
shown evidence of 
systemic efficacy 
56-60 
Vesicular 
stomatitis 
virus 
No 
Replicates selectively in 
interferon –resistant cells 
Preclinical 
studies only 
Preclinical 
evidence of 
systemic response 
25-27
 
Myxoma 
virus 
No 
Replicates selectively in Akt 
activated cells 
Preclinical 
studies only 
Preclinical 
evidence of 
systemic response 
61-64 
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1.3.2 Safety of Oncolytic Virotherapy 
Part of the attraction of oncolytic viruses as anticancer agents is their ability to 
replicate in cancer cells. The fact that cancer cell selectivity is innate, or can be 
engineered, decreases the risk of side-effects from damage to normal cells. To 
decrease the likelihood of virus-host genetic recombination, it is important that 
oncolytic viruses do not integrate with the host cell genome. From the clinical studies 
undertaken to date it is clear that oncolytic viruses are well tolerated with dose 
limiting toxicities rarely seen.  
 
Despite this apparent safety there is the potential for unforeseen effects both for the 
individual and the environment. The use of viruses that do not normally use humans 
as a host has caused concern from some authors
28
 particularly as there has been little 
investigation into whether the shed virus is genetically identical to the injected virus. 
As the genome of RNA viruses in particular can mutate rapidly there is the theoretical 
risk to the population as a whole.  
 
Another possible area of concern is the immunogenic effect of viruses. As many 
antigens expressed in tumour cells are shared by normal cells there is the potential for 
autoimmune disease. For example, vaccinia therapy of melanoma led to vitiligo in 
some patients due to the expression of identical antigens on melanoma cells and 
normal melanocytes
29
. It is known that the arming of replicating viruses with 
immunomodulatory genes can lead to unexpected consequences. In vivo mice studies 
with IL-4 producing ectromelia virus showed that genetically resistant mice could 
become susceptible to the virus with significant mortality
30
.  
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Given these potential adverse events it is critical that care is taken when designing and 
testing new agents especially in the clinical setting. 
 
1.3.3 Strategies to improve oncolytic virus therapy 
A number of factors are required for oncolytic viruses to be used effectively to treat 
patients with cancer. First and foremost they should be able to selectively infect and 
kill human cancer cells while causing minimal side-effects, or toxicity, to normal 
tissues. Ideally the life cycle of the virus should include rapid replication, cytolysis 
and spread, allowing effective amplification of each viral dose. The virus should act 
as a potent adjuvant, enabling the virus to stimulate immune-mediated anti-tumour 
response. To minimise the risk of virus-host genetic recombination events the virus 
should not recombine with the host cell genome. Finally, the virus should be able to 
be given systemically.  
 
With intravenous administration there are a number of barriers to optimal delivery of 
oncolytic viruses to tumours in vivo. When a virus is given systemically it is rapidly 
absorbed by the liver. Virus that escapes the liver can enter the circulation where it 
can be quickly neutralised through absorption by blood cells, through the complement 
cascade or by neutralising antibodies
31
. This is particularly true where there is pre-
existing exposure to the virus. For a virion to access the tumour, it must leave the 
circulation, crossing the vascular endothelium against a gradient of interstitial fluid 
pressure. Once in the tumour microenvironment the spread of the virus is further 
limited by the resident, or infiltrating, leukocytes.    
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 A possible strategy to increase systemic delivery of oncolytic viruses is to mask them 
from antibody neutralisation with chemical conjugates. Coating adenovirus with 
multivalent co-polymers of poly N-(2-hydroxypropyl)methacrylamide renders the 
virus resistant to antibodies
32
. This masking of the virus also prevents complement 
activation and reduces uptake of the virus by the liver cells. The downside to such an 
approach is that the infectivity of the virus can be affected through conjugation of its 
cell attachment protein
33
. Another issue is the technical difficulty of coating the virus 
and the cost.  
 
An alternative approach is the use of cell carriers to chaperone viral particles within 
the circulation. Various carrier cells, including T cells
34
, monocytes, endothelial 
cells
35
, tumour cells and dendritic cells
36
 have been shown to prevent viral elimination 
when given systemically. Generally, cell carriers with inherent tumour tropism, such 
as immune cells, are advantageous in enhancing viral delivery and have been used for 
this purpose in pre-clinical studies
37
. Some researchers have combined this approach 
with the use of cell carriers that are active against the tumour such as antigen-specific 
T cells
38
.  
 
Targeting the production of antiviral antibodies to enhance the delivery of oncolytic 
viruses has been evaluated in pre-clinical studies. Combining cyclophosphamide, 
which inhibits neutralising antibody production, with HSV, reovirus, or adenovirus 
has been shown to increase anti-tumour efficacy
39,40
. The combination of 
immunosuppressive drugs and reovirus will be discussed in more depth later in this 
introduction. The use of standard anticancer therapeutics, such as radiotherapy and 
cytotoxic chemotherapy, together with oncolytic agents has also demonstrated 
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increased efficacy, which may in part be due to the immune suppressive nature of 
these agents. 
 
Another possible benefit of combining cytotoxic agents with oncolytic viruses is their 
effect on the tumour microenvironment. Agents that induce apoptosis have been 
shown to increase the void space, intratumoural spread, and therapeutic efficacy of 
HSV if given prior to its intratumoural delivery
41
. Cytotoxic agents may effect the 
composition of the extracellular matrix, which in turn may influence viral movement 
and spread. The tumour vasculature is also a potential target in improving viral 
delivery to the tumour cells. The potential for viral escape through tumour blood 
vessels that are disorganised and leaky is counterbalanced by high interstitial fluid 
pressure and a thickened basement membrane. Antiangiogenic therapy, with 
antibodies to VEGF or mTOR inhibitors, transiently normalises the vasculature and 
lowers the interstitial fluid pressure
42
. A study using the mTOR inhibitor, RAD001, 
combined with an adenovirus showed increased efficacy in a colon cancer model, 
which was thought partly to be due to its antiangiogenic properties
43
. 
 
Other considerations for optimising oncolytic virotherapy include defining the best 
dosing regimen for each virus (whether bolus or infusion), identifying predictive 
factors for efficacy and an improved understanding of viral replication, localisation 
and kinetics in humans
44
. 
 
1.3.4 Adenoviruses 
Human adenoviruses are non-enveloped, double-stranded DNA viruses that can cause 
upper respiratory tract infections. Though they infect both dividing and non-dividing 
cells, they do not integrate into the host genome. Wild-type adenoviruses were 
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assessed clinically in the 1950s. However, increasing knowledge of the function of the 
viral proteins has allowed genetically modified adenoviruses to be developed allowing 
greater selectivity. The first engineered replication-selective virus to be used in 
humans, ONYX-015, has a deletion in the E1B region which restricts replication in 
cells lacking a normal p53
45
. Eighteen phase I/II trials have now been completed with 
ONYX-015. 
Early trials looked at the intratumoural injection of ONYX-015 into head and neck, 
and pancreatic cancers
46,47
. Side-effects included flu-like symptoms and injection site 
pain. Durable complete responses were not recorded, though in head and neck cancers 
transient antitumour effects were documented. No response at tumours distant to the 
site of injection was seen.   
Subsequent trials assessed the delivery and also the combination of ONYX-015 with 
chemotherapy.  A phase II trial of 37 patients with recurrent head and neck cancer 
tested the combination of intralesional ONYX-015 with intravenous cisplatin and 5-
fluorouracil
48
. The response rate was higher than in historical controls with 
chemotherapy alone, and tumours that received combination treatment had a 
significantly higher response rate than tumours treated with either treatment alone. 
There was no difference in toxicities experienced by the combination group compared 
with either agent alone. A phase III trial using a similar strain of adenovirus, H101, in 
combination with cisplatin-based chemotherapy has been completed in China. There 
was deemed to be a significant increase in the response rate in the combination group 
but results for survival were not adequately collected
49
. 
1.3.5 Herpes Simplex Virus 
Herpes Simplex virus-1 (HSV-1) is an enveloped, double-stranded DNA virus. Its 
gamma-34.5 gene product inhibits the IFN/dsRNA-dependent protein kinase R 
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response mechanism allowing it to replicate in non-dividing cells. To make HSV-1 
replication-conditional this gene product can be deleted. Four strains with deletions in 
this gene have been assessed in clinical trials.   
The HSV-1 1716 strain has been assessed in patients with glioblastoma and 
melanoma. Intratumoural administration was well tolerated, but no objective 
responses were reported
50
. The G207 strain was also well tolerated intratumourally in 
patients with glioblastoma, but no data on response was obtained
51
. The HSV vector 
OncoVEX
GM-CSF
, which has deletions in ICP47 as well as gamma-34.5 and is armed 
with a GM-CSF transgene insertion, has been evaluated in a phase I trial
52
. Patients 
with cutaneous metastases from solid tumours received intralesional virus. There were 
no significant toxicities and inflammation of the injection site was the dose-limiting 
toxicity. The injected tumours showed evidence of necrosis, but no systemic efficacy 
was demonstrated.  
 
1.3.6Vaccinia Virus 
Vaccinia virus is an enveloped, double-stranded DNA virus. It has a number of 
advantages over other oncolytic viruses including an extensive safety record as a 
vaccine for smallpox, a broad host range, short replication cycle, easy manipulation, 
and replication exclusively within the cytoplasm eliminating any risk of integration. 
Intratumoural and intravenous efficacy has been demonstrated with no serious adverse 
events reported and mild side-effects
53,54
. It can be made partially selective for growth 
in dividing cells by selecting for a deletion in the thymidine kinase gene. JX-594, one 
such strain which also expresses GM-CSF, has been tested intratumourally in a phase 
I study in patients with cutaneous melanoma
55
. There was evidence of tumour 
response in five of the seven patients treated and also objective regression of distant 
dermal metastases in four patients.  
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1.3.7 Newcastle Disease Virus 
Newcastle Disease Virus (NDV) is an avian virus belonging to the 
paramyxomaviridae family which are negative sense single-stranded RNA viruses. 
NDV is not pathogenic to humans and tumour selectivity is thought to be due to viral 
enhancement of the sensitivity of neoplastic cells to the cytotoxic effects of TNF-α56. 
Initial preclinical studies showed the potential oncolytic efficacy of NDV as early as 
1955
57
. Since then there have been numerous reports of clinical responses both when 
given intratumourally and intravenously
58,59
. The intravenous administration of the 
PV701 strain has been tested in a large phase I study including 79 patients
60
. Of the 
64 evaluable patients, 14 had stable disease for at least 4 months and 2 had a partial 
response. The treatment was well tolerated with fever, chills and nausea the most 
common side-effects. 
1.3.8 Myxoma Virus 
Myxoma virus is an enveloped double-stranded rabbit pox virus. It is non-pathogenic 
in humans and its oncolytic potential is based, at least in part, on its inability to grow 
in interferon-responsive cells
61
. It has been shown, however, to infect and kill over 
70% of human tumour cell lines
62
. The viral gene product M-T5 has been shown to 
regulate the ability of myxoma to propagate in human tumour cells. The interaction of 
M-T5 with two proteins, Cullin-1 and Akt-1/protein kinase B, appears to be 
responsible for this regulation by protecting MV-infected cells from cell cycle arrest 
and stress-induced cell death. 
While there have been no clinical trials with myxoma virus published to date, pre-
clinical studies show evidence of encouraging activity in a murine melanoma and 
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medulloblastoma model
63,64
.  Both studies demonstrated that efficacy was enhanced 
by the combination of myxoma virus with the mTOR inhibitor, rapamycin. 
 
1.4 Reovirus 
Reovirus is a wild-type ‘prototype’ oncolytic virus currently being investigated as a 
novel therapy for cancer. This section will give a broad outline of reovirus biology 
and pre-clinical data so far, and demonstrate its oncolytic capability and features 
which make it particularly attractive as a therapeutic agent. The clinical evaluation of 
reovirus is being led by centres in the United Kingdom and past and current studies 
are described. 
 
Reovirus is a member of the family reoviridae which includes six genera, three of 
which infect animals: rotavirus, orbivirus and reovirus. The name is a derivation of 
respiratory enteric orphan viruses, acknowledging that they can infect the respiratory 
and gastrointestinal system but are not associated with any known disease. Reovirus is 
generally regarded as benign but can infrequently be associated with upper respiratory 
symptoms resembling a flu-like illness or mild gastrointestinal symptoms such as 
diarrhoea. Reovirus is ubiquitous and has been isolated from untreated sewage, 
stagnant water and rivers worldwide 
65,66
.  Exposure to reovirus is very common in the 
human population and up to 100% of human adults are seropositive 
67,68
. 
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1.4.1 Reovirus structure 
All members of the Reoviridae family have similar morphology. Reovirus virions 
consist of a non-enveloped, icosahedral capsid with a double shell of proteins. The 
genome is comprised of double-stranded RNA which is split into 10 segments of three 
sizes, designated L, M and S. A simplified representation of the structure of reovirus 
is given in Figure 1.1. A schematic representation of reoviral replication is shown in 
Figure 1.2. 
 
 
Figure 1.1: Reovirus Structure 
Reoviruses are non-enveloped and have an outer (blue) and inner (orange) icosahedral 
capsid. The inner capsid remains intact after endocytosis and is know as the core. In 
the centre is the double-stranded RNA (dsRNA) genome which contains ten segments 
in 3 size classes: L, M and S.  
 
S 
M 
L 
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Figure 1.2: Reovirus replication. The reovirus lifecycle begins with binding to cell 
surface sialic acid 
69
 and junctional adhesion molecule 1 (JAM1) 
70
, followed by 
endocytosis. Within the endosome, virions are converted to infectious subvirion 
particles (ISVPs): the outer capsid proteins are degraded by endosomal proteases and 
broken up into smaller fragments. The ISVPs are then further processed within the 
endosome to particles that are no longer infectious but are a transcriptionally active 
core particle (gold). The core particle fuses with the endosomal membrane and enters 
the host cytoplasm 
71
 (green). This process activates the viral RNA-dependent RNA 
polymerase and transcription occurs within the core particle. Primary transcripts and 
protein products assemble to form RNA assortment complexes, which then carry out 
secondary transcription to produce more virions which are then released. 
6. Transcription 
7. Translation 
8. Final Assembly 
1. Virion 
3. Endocytosis 
4. Proteolysis 
5. Core 
9. Progeny Virions 
2. JAM1/sialic acid 
receptor 
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1.4.2 Reoviral oncolysis. 
 
The oncolytic capability of reovirus was first recognised in the 1970s when wild-type 
reovirus was shown to replicate in transformed cells 
72
 but not in normal cells. Cells 
expressing high levels of epidermal growth factor receptor (EGFR) and v-erbB (a 
truncated mutant of EGFR) were both susceptible to reovirus infection 
73
 suggesting 
an intracellular factor associated with the EGF receptor which was permitting reoviral 
replication 
74
. Further work identified the Ras pathway, a downstream signalling 
pathway from the EGF receptor, as being crucial to sensitizing cells to reovirus.  The 
Ras protein is a small G protein which is activated when guanosine triphosphate 
(GTP)-loaded and in turn leads to the activation of downstream pathways which play 
an important role in cellular differentiation, proliferation and motility, and together 
can act synergistically to promote tumourigenesis. Ras can become activated either 
via mutation of the protein or via over expression of the upstream EGF receptor or 
other receptor tyrosine kinases. Ras activating mutations are present in 30-40% of all 
human tumours 
75
.  
 
Reoviral infection of normal cells leads to the activation of the double-stranded RNA-
activated protein kinase (PKR).  PKR is a serine/threonine protein kinase which 
requires dsRNA binding and phosphorylation to become activated 
76
. The main role of 
PKR is to defend cells against viral infection and to contribute to the antiproliferative 
response of interferon following viral infection. However, in cells harbouring an 
activated Ras mutation PKR is not phosphorylated and remains in its inactive state. 
Reoviral protein synthesis continues unchecked, the virus replicates within the cells 
and cell lysis occurs 
77
. This mechanism is illustrated in Figure 1.3.  
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Figure 1.3: Mechanism of tumour-selective replication of reovirus.  
Viral infection occurs in normal and transformed cells through sialic acid/JAM-1 
receptors. In normal cells, the presence of double-stranded RNA (dsRNA) in the 
cytoplasm leads to activation (phosphorylation) of PKR and, through subsequent 
activation of eIF2a, shutdown of viral protein synthesis. In contrast, in tumour cells 
with activated Ras, PKR is not activated and viral replication proceeds. (By kind 
permission of K. Harrington) 
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1.4.3 Preclinical data 
 
Over 80% of cell lines originating from virtually all common tumour types have been 
found to be susceptible to reoviral oncolysis 
78-80
. Intratumoural injection of reovirus 
causes regression of syngeneic and xenograft tumours in immune competent and 
deficient animal models, respectively. Human glioma xenografts regressed by 80% 
after a single intratumoural injection of reovirus 
80
. Similar efficacy has been 
demonstrated in breast 
78
, lymphoma 
81
, colon and ovarian cancer 
79
 xenograft models.  
 
As the best understood mechanism of selectivity of reovirus replication for malignant 
cells was its relationship with Ras activation, early preclinical work focused on 
models involving tumours with activated Ras. These include pancreatic (exocrine) 
adenocarcinoma 
82
, malignant glioma 
83
, medulloblastoma 
84
 and breast 
adenocarcinoma 
78
. However, subsequent studies have shown that activating Ras 
mutations are not a prerequisite for reoviral cytotoxicity as some cell lines with wild-
type Ras are also susceptible 
85
. The mechanism of selectivity in these cells is not 
known. There is now accumulating evidence that translational regulation via PKR-
inactivation may not be the only mechanism for the preferential replication of reovirus 
in Ras-transformed cells. Two recent studies have shown that virus uncoating, 
assembly, and apoptosis-dependent release is enhanced in Ras-transformed cells 
86,87
. 
Whether any of these factors play a part in cells without an activated Ras pathway has 
not been determined. 
 
One of the key factors limiting the potential of viral therapy for cancer is the 
induction of a rapid and potent anti-viral humoral response. Attenuating this response 
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has long been seen as a vital component in the development of this class of anti-
tumour agent. Studies have shown early in vivo responses to systemic reovirus in both 
subcutaneous and metastatic models, only for the tumour to resume growth after 
several weeks despite continued therapy. This correlates with the development of a 
measurable antibody response mounted against reovirus 
88
. Combining i.v. reovirus 
treatment with immune suppression using cyclosporine A or anti-CD4/anti-CD8 
antibodies resulted in further reduction in tumour size and a considerable prolongation 
in survival, compared with viral therapy alone. Similarly, cyclophosphamide was also 
successful in modulating neutralising antibody response to reovirus when 
administered in a very specific (metronomic) dosing regimen 
39
. However, there are 
obvious risks with deliberate attenuation of the natural protective immune responses 
to reoviral infection with respect to non-cancer tissue. Although co-administration of 
reovirus and cyclophosphamide was associated with improved efficacy, new toxicities 
were evident by the observation of increased viral replication in multiple organs and 
cardiomyopathy. By altering the schedule using metronomic dosing of 
cyclophosphamide (3 injections separated by 6 days) significantly greater anti-tumour 
effects were demonstrated compared to either agent alone, with minimal replication in 
essential organs. This highlights the ‘window of opportunity’ with respect to 
combined immune modulation and reovirus treatments: a careful reduction rather than 
abrogation of humoral response.  
 
Given the potential risk of reovirus-induced toxicity in immunocompromised hosts, 
some authors have suggested an alternative strategy that would modify wild-type 
reovirus to improve selectivity. Due to its unique genetic composition, reovirus has 
not, until recently, been amenable to standard genetic modification. However, 
adaptation of reovirus in persistently infected cultured cells has been seen and these 
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attenuated viruses appear to be less pathogenic to non-malignant cells while retaining 
their oncolytic potential
89-91
. A novel reverse genetics system for dsRNA viruses that 
has recently been described may allow further research into reovirus attenuation 
92
. 
 
Although reovirus alone has shown impressive anti-tumour effects in tumour models, 
its future potential as a mainstream cancer therapeutic is likely to be in combination 
with other treatment modalities. The combination of reovirus and radiotherapy has 
been shown to be synergistic (and not simply additive), and to enhance cell kill in 
both in vitro and in vivo models 
93
. This enhanced cytotoxicity was seen in a number 
of cancer cell lines, but was more significant in cell lines with moderate sensitivity to 
reovirus alone. The mechanisms underlying the observed synergy remain to be 
defined, but appear to be due to increased apoptosis rather than necessarily an 
increase in viral replication in the tumour.  
 
In a similar way, combination of chemotherapy and reovirus has resulted in enhanced 
cytotoxicity in a wide range of cancer cell lines as shown by isobolographic 
analysis
94,95
 and tumour growth delay in in vivo models. While the mechanisms of cell 
death when chemotherapy and reovirus are co-administered are likely to be different 
depending on the cell line and chemotherapeutic agent used, an increase in apoptotic 
cells was seen with combination compared to reovirus alone. With the combination of 
cisplatin and reovirus there was evidence of enhanced viral replication compared to 
reovirus alone but only within the tumour itself and not distant organs. The addition 
of cisplatin had no effect on the humoral response to reovirus in a murine in vivo 
model but did abrogate the inflammatory cytokine response. It has also been observed 
that there is increased sensitivity of tumour cells to reovirus during S and G2/M 
phases of the cell
96
. Cells pretreated with hydroxyurea, or thymidine, were more 
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sensitive to reovirus particularly in S and G2/M phases and there was evidence of 
increased viral replication. This finding was confirmed in vivo when hydroxyurea was 
given prior to intratumoral reovirus.  
 
1.4.4 Reovirus and Antitumour Immunity 
 
As well as the potential to inhibit the efficacy of oncolytic viruses through the 
production of anti-viral antibodies, the immune system may also augment therapy by 
bystander immune activation. Reovirus infection of tumour cells can enhance 
recognition by the immune system and help prime generation of an anti-tumour 
response. The release of tumour-associated antigens in the context of reovirus induced 
cell death can facilitate coincident innate immunity and subsequent specific priming 
against tumour-associated antigens.  
 
Reovirus infection of melanoma cells has been shown to result in the release of pro-
inflammatory cytokines including: interleukin-1, interleukin-6, interleukin-8, 
RANTES, eotaxin, MIP-1α, and MIP-1β97,98. It also reduces the production of the 
immunosuppressive cytokine interleukin-10. This inflammatory response has been 
shown to cause bystander toxicity against reovirus-resistant tumour cells in vitro, thus 
providing another mechanism by which reovirus may exert its cytotoxic effects. The 
release of these inflammatory mediators acts to recruit other cells of the immune 
system to the tumour microenvironment. Reovirus directly activates dendritic cells, 
key regulators of the innate and adaptive immune response
99
. These reovirus-activated 
dendritic cells then support innate killing by NK cells and also T cells. Supporting this 
concept is the finding that reovirus infection in both a murine melanoma model, and 
 37 
human melanoma cells in vitro, can generate adaptive anti-tumour immune 
responses
100
. 
 
In a murine melanoma model using the reovirus-resistant B16ova cell line which 
expresses low levels of JAM-1, a single dose of reovirus-loaded T cells was able to 
purge lymph node and splenic metastases
101
, whereas in mice with severe combined 
immunodeficiency reovirus failed to reduce tumour size in B16ova or reovirus-
sensitive metastases. This suggests that an intact immune system is required for in 
vivo efficacy in this model. The same authors also showed that neither direct reovirus-
induced oncolysis nor reovirus replication was required for the generation of anti-
tumour immunity in an in vitro human system. Furthermore, the cytokine and 
chemokine response to reovirus infection appears to be PKR/NF-B mediated and is 
able to prime the innate and adaptive anti-tumour activity even after live virus has 
been removed
102
. 
 
Taken together these data imply a critical role for the immune system in mediating the 
efficacy of reovirus therapy. As stated before, this may seem at odds with the finding 
that tumour response can be enhanced by combining reovirus with 
immunosuppressive agents such as cyclophosphamide. While the improvement in 
viral delivery achieved by abrogating the viral antibody response is likely to be 
important for intravenous delivery of reovirus and the potential for increased 
persistence at the tumour site, this does not preclude the importance of the immune-
mediated antitumor responses. The likelihood is of a fine balance between these 
factors. A strategy that could enhance antitumor immunity while improving delivery 
of the virus has yet to be determined. 
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1.4.5 Clinical Data 
 
A number of clinical trials involving reovirus have been completed or are on-going. 
These include studies assessing different strategies for the delivery of reovirus to the 
tumour as a single agent, as well as the potential of reovirus in combination with other 
treatment modalities. A summary of these clinical trials is provided in Table 1.2. 
 
There are a number of different methods for virus quantification. The two most 
common methods that are used in the trials described in this chapter are viral plaque 
assays that determine the number of plaque forming units (pfu) in a viral sample, and 
50% tissue culture infective dose (TCID50). TCID50 is an endpoint dilution assay that 
quantifies the amount of virus required to kill 50% of inoculated tissue culture cells. 
While the relationship between the two is approximately 1 PFU = 7 TCID50 in reality 
this may not hold true given the differences in assay set up and sensitivity of the virus 
to the experimental conditions. 
 
Intralesional delivery of reovirus has been assessed both as monotherapy and in 
combination. Patients with a variety of malignancies were treated with intratumoural 
(i.t.) reovirus in a phase I study at escalating dose levels, ranging from a single 
injection of 1x10
7
 plaque forming units (pfu) to three injections of 1x10
10 
pfu. Only 
grade 2 toxicities or less were reported, including occasional headaches and flu-like 
symptoms. Reovirus antibody titres increased in all the patients after treatment. 
Objectively, one patient had a complete response and two had a partial response. 
Eight patients showed stabilization of their local disease
103
. 
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Table 1.2 – REOLYSIN Clinical Studies 
 
Study 
No. Phase Details Tumour Type Investigational Site Status Outcome 
 
REO 01 
 
I 
Single agent, 
intralesional 
injection 
Advanced  Solid 
Tumours 
(Percutaneous) 
Tom Baker CC  
Calgary, AB 
Completed 
19 patients 
No MTD 
reached 
 
REO 02 
 
I 
Single agent, 
intraprostatic 
injection 
 
Prostate Cancer 
Tom Baker CC  
Calgary, AB 
Completed 
6 patients 
No MTD 
reached 
 
REO 03 
 
I 
Single agent, 
intralesional 
injection 
Recurrent 
Gliomas 
Tom Baker CC 
Calgary, AB 
Completed 
12 patients 
No MTD 
reached 
 
REO 04 
 
I 
Single agent, 
intravenous 
administration 
Advanced  Solid 
Tumours 
 
Montefiore CC 
Bronx, NY 
Completed 
18 patients 
No MTD 
reached 
 
 
REO 05 
 
 
 
I 
 
Single agent, 
intravenous 
administration 
 
Advanced  Solid 
Tumours 
 
Royal Marsden Hosp  
Sutton, UK 
St. Georges Hosp  
London, UK 
Royal Surrey Hosp  
Surrey, UK 
 
Completed 
33 patients 
 
No MTD 
reached 
 
 
 
 
REO 06 
 
 
Ia 
 
 
Intralesional 
administration 
combined with 
radiotherapy 
Advanced  Solid 
Tumours 
 
(Percutaneous) 
Royal Marsden Hosp  
Sutton, UK 
St. James Hosp 
Leeds, UK 
 
Completed 
12 patients 
 
 
No MTD 
reached 
 
Ib 
Advanced  Solid 
Tumours 
 
(Percutaneous) 
Royal Marsden Hosp  
Sutton, UK 
St. James Hosp  
Leeds, UK 
 
Completed 
11 patients 
 
No MTD 
reached 
 
REO 07 
 
 
I/II 
Single agent, 
intralesional 
infusion 
Recurrent 
Gliomas 
Univ. of Alabama 
Birmingham, AL 
Completed 
15 patients 
No MTD 
reached 
 
 
 
REO 08 
 
 
 
 
II 
 
 
 
Intralesional 
administration 
combined with 
radiotherapy 
 
 
Advanced  Solid 
Tumours 
 
(Percutaneous) 
Royal Marsden Hosp  
Sutton, UK 
St. James Hosp 
Leeds, UK 
Christie Hosp 
Manchester, UK  
Southampton Hosp 
Southampton, UK 
 
 
 
Completed 
16 patients 
 
 
No MTD 
reached 
 
REO-09 
  
 
I 
Intravenous 
administration with 
concurrent 
Gemcitabine 
 
Advanced  Solid 
Tumours 
 
 
Royal Marsden Hosp  
Sutton, UK 
 
 
Completed 
16 patients 
 
No MTD 
reached 
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Study 
No. Phase Details Tumour Type Investigational Site Status Outcome 
 
 
REO-10 
 
 
 
I 
Intravenous 
administration with 
concurrent 
Docetaxel 
 
Advanced  Solid 
Tumours 
 
Royal Surrey Hosp 
Guildford, UK 
Guy’s Hosp, London 
Churchill Hosp, 
Oxford, UK 
 
Completed 
24 patients 
 
No MTD 
reached 
 
 
REO-11 
 
 
 
I 
Intravenous 
administration with 
concurrent 
Paclitaxel and 
Carboplatin 
 
Head and Neck 
Tumours 
 
 
Royal Marsden Hosp  
Sutton, UK 
 
 
Completed 
31 patients 
 
No MTD 
reached 
 
 
REO-12 
 
 
 
I 
Intravenous 
administration 
combined with 
Cyclophosphamide 
 
Advanced  Solid 
Tumours 
 
Royal Marsden Hosp  
Sutton, UK 
Royal Surrey Hosp 
Guildford, UK 
Guy’s Hosp, London 
 
Commenced 
March 2008 
 
 
No MTD to 
date 
 
REO-14 
 
II 
Single agent, 
intravenous 
administration 
Metastatic 
Sarcomas (bone 
and soft tissue) 
US 
Completed 
53 patients 
 
- 
NCI 
Trial 
 
II 
Intravenous and 
Intraperitoneal 
administration 
Metastatic 
Ovarian 
Tumours 
US 
Commenced 
mid-2008  
 
- 
REO-15 II 
Intravenous 
administration in 
combination with 
Paclitaxel and 
Carboplatin 
 
Head and Neck 
Tumours US 
Ongoing 
 
- 
REO-16 II 
Intravenous 
administration in 
combination with 
Paclitaxel and 
Carboplatin 
 
Non-small cell 
Lung cancers US Ongoing - 
REO-17 II 
Intravenous 
administration in 
combination with 
Gemcitabine 
Advanced 
Pancreatic 
cancer 
 
US 
Ongoing - 
REO-18 III 
Intravenous 
administration in 
combination with 
Paclitaxel and 
Carboplatin 
 
Squamous  cell 
carcinomas of 
the head and 
neck 
UK Ongoing - 
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Twelve patients with recurrent gliomas (ten of the patients had glioblastoma 
multiforme, one anaplastic astrocytoma and one anaplastic oligoastrocytoma) were 
treated with intrlesional reovirus at 3 dose levels in a further phase I study
104
. The 
doses were 1 x 10
7
, 1 x 10
8
 and 1 x 10
9 
tissue culture infectious dose-50 (TCID50). 
The treatment was well tolerated with no grade 3 or 4 toxicities. Serum specific 
antibodies increased above the baseline in ten patients, though viral RNA was not 
detected in the serum of any of the patients. One patient had stable disease and all the 
others had progressive disease. Three patients survived for more than a year, while 
one patient survived for 54 months after the reovirus was administered. Half the 
patients had surgery after the reovirus treatment and histopathological analysis 
confirmed persistent disease with no clear evidence of definite viral infection of the 
tumour cells. A phase 2 study is now underway assessing intralesional, infusional 
delivery of reovirus in patients with recurrent gliomas. 
 
Intralesional reovirus as monotherapy in patients with localised (T2) prostate cancer 
has also been assessed
105
. The primary endpoints of this study were to examine safety 
and the effects on prostate histology post-therapy and post-prostatectomy. Six patients 
were treated with a single dose of 5x10
9
 TCID50 reovirus injected directly into the 
prostate gland three weeks prior to prostatectomy. Results showed evidence of 
antitumor activity with apoptotic tumour cell death in four of six patients and a 
significant CD8 T-cell infiltration in the injected areas. The treatment was well 
tolerated with no new urinary symptoms. In one patient, PSA levels dropped by 53% 
and the prostate gland shrank by 67% from just prior to reovirus injection to surgical 
removal of the prostate gland three weeks later. 
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Intralesional administration of reovirus has been combined with radiotherapy
106
. The 
patients, all of whom had advanced solid tumours, received intratumoural injections 
of reovirus with concurrent fractionated radiotherapy. The primary objective was to 
assess the safety of the intervention, but also to assess tumour response, viral 
replication and development of immune response. In all, 23 patients were treated. 
Treatment was well tolerated with predominantly grade 1 and 2 toxicities including 
fatigue, fever and lymphopenia. No dose-limiting toxicity was observed. Of the 14 
evaluable patients all had either stable disease or partial response by RECIST criteria. 
Though the study was not designed to evaluate the antitumour activity of reovirus, 
two patients had evidence of a systemic effect. One patient with oesophageal cancer 
who had radiotherapy to a supraclavicular nodal mass had a response in mediastinal 
nodes outside the radiation field. Another patient, with malignant melanoma, 
developed vitiligo in the treament area after injection with reovirus. A phase 2 study 
has been completed to further assess the response to combination treatment. 
 
Intravenous administration of reovirus as monotherapy has been assessed in two 
phase 1 trials. The objectives of the UK study
107
 were to determine the safety and 
feasibility of systemic administration of reovirus, as well as assessing viral 
replication, antiviral immune response and any antitumoural activity. In total 33 
patients were treated at 8 different dose levels, ranging from a single dose of 1 x 10
8
 
TCID50 to 3 x 10
10
 on five consecutive days. The maximum tolerated dose was not 
reached and toxicities were mild. The most common toxicities were fever, fatigue, 
headache, lymphopaenia and neutropaenia. Viral shedding was not demonstrated in 
serum, stool, sputum or urine samples. Most patients had anti-reovirus antibodies at 
baseline and significant induction of an antiviral immune response was demonstrated 
after the first cycle, with high antibody titres maintained in subsequent cycles at all 
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dose levels 
108
. Intratumoural virus replication was identified in post-treatment 
biopsies by electron microscopy. Responses were seen in a number of patients. One 
patient with metastatic prostate carcinoma had a 50% fall in his PSA associated with 
evidence of tumour necrosis and reduction of a lymph node on CT scan. Two other 
patients with colorectal cancer had a reduction in their CEA, and four other patients 
demonstrated stable disease. 
 
The concurrent US phase 1 trial
109
 using intravenous reovirus as monotherapy was a 
dose escalation study giving reovirus once every month with doses ranging from 1 x 
10
8
 to 3 x 10
10
. Of the 18 patients treated, eight demonstrated stable disease including 
a patient with progressive breast cancer who experienced 28.5% reduction in tumour 
volume. Again the treatment was well tolerated with only grade 2 toxicities of fever 
and fatigue observed. All patients developed neutralising antibodies to reovirus. 
 
A phase II trial of single agent intravenous reovirus has been completed in patients 
with sarcoma and lung metastases. The 52 patients enrolled in the study were treated 
every four weeks with 3 x 10
10
 TCID50. The treatment was well tolerated though 
grade 3 neutropaenia was observed in 16% of patients. Interim results showed that 
50% of patients had stable disease for over 8 weeks and 14% of patients had stable 
disease for over 24 weeks (poster presentation). The completed results have yet to be 
published. 
 
Further monotherapy studies include a phase I study of intravenous reovirus in 
patients with melanoma, and also a combination of intravenous and intraperitoneal 
reovirus in ovarian cancer patients. Both are still ongoing.  
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Four phase 1 trials assessing the combination of intravenous reovirus with cytotoxic 
chemotherapy: (i) gemcitabine (REO-009); (ii) docetaxel (REO-010); (iii) carboplatin 
plus paclitaxel (REO-011); and (iv) cyclophosphamide (REO-012) have been 
conducted to date. The combination of reovirus with these agents in vitro has been 
shown to be synergistic in a number of cell lines and animal models. The first three 
studies were regular phase I protocols in which conventional doses of standard 
cytotoxic drugs are combined with reovirus with the goal of studying safety and 
tolerability, and defining dose-limiting toxicity (DLT) and maximum tolerated dose 
(MTD). Detailed analysis of the effect of reovirus delivery on drug pharmacokinetics 
was performed. In addition, the effect of drug delivery on viral pharmacokinetics and 
pharmacodynamics was measured. Depending on the results of these initial analyses, 
it is anticipated that this programme will proceed to randomized phase II and III 
evaluation of reovirus plus chemotherapy in specified indications. 
 
The combination of docetaxel and reovirus, REO-010, will be presented in chapter 6. 
REO-009, assessing the combination of reovirus with gemcitabine, has been 
completed and the results published
110
. In all, 16 patients were enrolled and received 
47 cycles of reovirus. The initial study design dosed reovirus on five consecutive days 
with gemcitabine on day one only. This was poorly tolerated and therefore the 
protocol was amended to a single dose of reovirus up to 3 x 10
10
 TCID50. The first 
two patients experienced dose limiting toxicity including grade 3 liver enzyme rises 
and an asymptomatic grade 3 rise in Troponin I. It was shown that potential 
interaction between reovirus and gemcitabine could cause liver enzyme rises hence 
the change in the study protocol. However, the rise in liver enzymes was both short 
and reversible. Other toxicities were similar to the intravenous monotherapy trials and 
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the known side effects of gemcitabine. The neutralizing antibody response was 
assessed and was found to be attenuated both in time to development and peak height 
of the response. Of the 10 patients evaluable for response assessment two had a partial 
response and five had evidence of stable disease for at least 3 cycles amounting to a 
disease control rate of 70%. 
 
REO-011, a phase I/II trial assessing the combination of reovirus with carboplatin and 
paclitaxel, has completed recruitment and the results have recently been published
111
. 
A total of 31 heavily pre-treated patients, with a focus on squamous cell carcinomas 
of the head and neck, received the study treatment. Paclitaxel 175mg/m
2
 and 
Carboplatin AUC5 were given on day 1 with reovirus given on days 1-5 in doses 
ranging from 3 x 10
9
 to 3 x 10
10
. The treatment was well tolerated with typical side 
effects for both drugs. No maximum tolerated dose was reached. The majority of the 
patients with squamous cell carcinoma of the head and neck were considered platinum 
refractory. In Total 26 patients completed 2 cycles and were evaluable for 
effectiveness. One patient (3.8%) had a complete response, six (23%) had a partial 
response, two patients had significant responses in radiation pre-treated lesions that 
were not evaluable by RECIST, and 9 patients (34.6%) had stable disease. Eight 
patients (30.8%) had disease progression. Viral shedding was only seen in three of the 
13 patients assessed. The maximum level of neutralising antibody response was 
reached later than seen in previous studies with single agent  intravenous reovirus. 
 
The ongoing phase 1 study testing the combination of reovirus and cyclophosphamide  
is the most significant study in that it represents a new paradigm for clinical 
virotherapy in which direct modulation of the immune response is tested as a means 
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of achieving systemic viral delivery and efficacy. As such, it required a unique 
clinical trial design based directly on data generated in preclinical studies of the effect 
of immunomodulation on systemic viral delivery. The novelty of the study design lies 
in the fact that the primary endpoint is the effect of immunomodulatory chemotherapy 
on the level of the neutralising anti-reoviral antibody (NARA) response. In an open-
label, dose-escalating study design, intravenous cyclophosphamide will be given 3 
days before each 5-day schedule of reovirus, with the treatment repeated every 4 
weeks. This schedule directly mirrors preclinical murine data 
39
. The result of a 
NARA assay on day 15 of each treatment cycle will be used as an indicator of 
immune modulation. For each dose level, immune modulation will be considered 
effective if the rise in NARA titre on day 15 of cycle 1 and/or 2 is at least 10-fold 
lower than that observed previously in the phase I study of intravenous reovirus 
108
. 
 
Reovirus has considerable potential as an anticancer agent for a wide range of 
malignancies, and this may be realised through different routes of administration. As 
no genetic modification of the virus is required for its oncolytic activity, and most 
humans have low level pre-existing immunity there are obvious attractions in terms of 
safety and regulation. Clinical trials show the agent to be well tolerated and safe. 
However, significant obstacles such as the brisk induction of anti-reoviral immunity 
need to be addressed and this is the focus of one current study. Significantly, no MTD 
has been reached in any of the reovirus studies and as viruses do not adhere to 
conventional dose-response relationships, optimum dose schedules remain 
unresolved. Current studies have now expanded into combination strategies with 
radiotherapy and chemotherapy.  
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The following work presents data exploring some of the strategies discussed to 
improve reovirus oncolysis. Firstly, we tested the combination of reovirus and the 
mTOR inhibitor rapamycin both in vitro and in vivo. mTOR inhibitors are novel 
anticancer agents that have a number of potentially synergistic effects with oncolytic 
viruses including altered cell signalling, immune suppression and altered 
angiogenesis. Secondly, we interrogated the unexpected finding of increased EGFR 
gene expression seen on microarray when mouse melanoma B16 cells were exposed 
to reovirus. Given that the Ras pathway is thought to play a key role in reovirus 
selectivity and EGFR is an upstream component, we wanted to explore whether the 
expression of EGFR altered reovirus oncolysis. Finally, we present the results of a 
phase I trial looking at the combination of intravenous reovirus with intravenous 
docetaxel in patients with advanced malignancies resistant to standard therapies. 
 48 
 
 
 
 
 
Chapter 2 
 
 
 
Materials and Methods 
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2.1 Cell Culture 
2.1.1 Cell Lines 
Mouse malignant melanoma cells, B16.F10 (CRL-6475), Mel888, and K1735, mouse 
fibroblasts, L929 (CCL-1), human prostate adenocarcinoma cells, PC3 and DU145 
(CRL-1435 and HTB-81), human clear cell carcinoma of the kidney cells Caki-2 
(HTB-47), human breast adenocarcinoma cells, MCF7 (HTB-22), human colon 
adenocarcinoma cells, HT29 (HTB-38), human pancreatic adenocarcinoma cells, 
PSN-1, and human fibroblasts MRC-5 (CCL-171), were purchased from American 
Tissue Culture Collection (ATCC). Human oral squamous cell carcinoma, Cal-27, 
was kindly given by Dr. K Harrington (ICR, UK)   
2.1.2 Cell Handling 
Mouse cell lines were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) and 
human cell lines in RPMI-1640 (both Sigma). All media was supplemented with 
2mM GlutaMAX-1 supplement (Invitrogen),
 
100 units/ml penicillin, and 100 units/ml 
streptomycin (Sigma) and either 10% (v/v) foetal calf serum (FCS) for routine 
passage or 2% (v/v) FCS for experimental work. Cell culture work was carried out in 
a sterile environment provided by a laminar flow hood with double HEPA filter. Cell 
lines were regularly tested for mycoplasma infection. Passage of cell cultures was 
carried out when cells were approaching confluence: every 3-7 days depending on the 
cell line. Cells were washed with Hanks Balanced Salt Solution (HBSS) to remove 
any foetal calf serum and then 0.05% trypsin (Sigma-Aldrich) was added. Once the 
cells had been mobilised fresh medium containing foetal calf serum was added to stop 
the trypsinisation. The cell suspension was then centrifuged at 1500rpm for 3 minutes. 
The cell pellet was resuspended in the appropriate medium and plated out in the 
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required dilution. Cells were incubated at 37°C and either 5% or 10% CO2 depending 
on the cell line. 
In order to maintain stocks of the various cell lines, cells were regularly frozen down. 
Cells in log phase of growth were pelleted and resuspended at 10
6
-10
7
cells/ml in 
complete medium and an equal volume of 20% DMSO in foetal calf serum added. 
1ml aliquots were transferred to labelled cryotubes which were then placed in a 1°C 
freezing container and stored overnight in a -80°C freezer. The isopranol in these 
containers allows for slow freezing at approximately 1°C/minute. Cells were then 
transferred to liquid nitrogen storage the following day. Recovery of cells from liquid 
nitrogen storage was performed by rapid thawing in a 37°C water bath. Thawed cells 
were washed in 10ml of medium, harvested by centrifugation (1500rpm for 3 
minutes) and were then transferred to 75cm
2
 flasks containing fresh culture medium. 
 
2.1.3 Reovirus Stocks and Rapamycin 
Reovirus type 3 Dearing strain Reolysin® stocks at 3.45 x 10
10
 tissue culture infection 
dose 50 (TCID50/mL) were supplied by Oncolytics Biotech. Inc. (Calgary, Canada). 
Virus stock titre and virus stability was measured by standard plaque assay of serially 
diluted samples on L929 cells. Six-well plates were seeded with 1 x 10
6
 L929 cells 
per well and infected with dilutions of viral stocks. After 3h incubation at 37
o
C, the 
virus solution was removed and the wells were overlaid with a 1:1 mixture of 2% 
SeaPlaque agarose (Cambrex Bio Science Rockland, Inc, ME) and 2 x MEM 
(Invitrogen) supplemented to a final concentration of 5% (v/v) FCS, 100 units/ml 
penicillin/streptomycin and 2mM GlutaMAX-1. Wells were stained with 500µL 
0.03% neutral red (Sigma) in PBS 72h post-infection and plaques were counted 3 to 4 
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hours later. The reovirus stocks were stored at -80°C in 200μl aliquots at a 
concentration of 3 x 10
9
 plaque forming units (pfu). 
Rapamycin, 25mg, was purchased from LC Laboratories, dissolved in 7.5ml of 
absolute ethanol and stored at -20°C. 
 
2.1.4 MTS Assay 
Cell viability was quantified using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Sigma-
Aldrich). This assay is based on the reduction of the tetrazolium salt, MTS, to a 
coloured formazan compound by living cells in culture. This assay is similar to the 
MTT assay with the advantage that the formazan product of MTS reduction is soluble 
in cell culture medium, unlike MTT which has to be dissolved in DMSO. Metabolism 
in living cells produces “reducing equivalents” such as NADH or NADPH. These 
reducing compounds pass their electrons to an intermediate electron transfer reagent 
that can reduce MTS into the aqueous, formazan product. When the cell dies, it 
rapidly loses the ability to reduce tetrazolium products. Therefore the production of 
the coloured formazan compound is proportional to the number of viable cells in 
culture. 
 
2.1.5 In vitro survival assay 
Cells were plated in 96-well plates at a density of 7.5 x 10
3
 cells per well. After 24 
hours, they were infected with known dilutions of reovirus and rapamycin, either 
alone or in combination.  Control wells received an equivalent volume of assay 
medium. After 48h incubation, cell viability was quantified using the CellTiter 96 
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AQueous One Solution Cell Proliferation Assay reagent 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS; Promega) 
according to manufacturer’s instructions. Briefly, 20µl of MTS reagent in 180µl of 
fresh medium was added to each well. Following incubation at 37
o
C for 1-4 hours, 
absorbance was measured at 495nm using a Beckman Coulter plate reader. Survival 
was calculated as a percentage compared to untreated cells using the formula:  
   (Treated Value – background) 
% Cell Survival   =   
_________________________________________
 x 100  
(Untreated Value – background)  
  
All experiments were repeated a minimum of three times. 
 
2.1.6 Assessment of Synergy 
The effect of combining agents on cell proliferation was assessed by calculating 
combination index (CI) values using CalcuSyn software (Biosoft). Derived from the 
median-effect principal of Chou and Talalay, the CI provides a quantitative measure 
of the degree of interaction between two agents.  
Analysis using the CalcuSyn programme performs optimally when data is collected 
from a constant ratio combination design experiment. Typically the combination 
agents are chosen at their equipotent ratio (eg at the ratio of their IC50s) and mixtures 
of the agents at 4x, 2x, 1x, 0.5x and 0.25x IC50 are prepared and tested, e.g. 
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Agent 1 
 
 
 
 
 
 
 
Agent 
2 
 
 
0 0.25x 
(ED50)1 
0.5x 
(ED50)1 
1x 
(ED50)1 
2x 
(ED50)1 
4x 
(ED50)1 
 
0 
Control 
(fa)0 
 
(fa)1 
 
(fa)1 
 
(fa)1 
 
(fa)1 
 
(fa)1 
0.25x 
(ED50)2 
 
(fa)2 
 
(fa)1,2 
    
0.5x 
(ED50)2 
 
(fa)2 
  
(fa)1,2 
   
1x 
(ED50)2 
 
(fa)2 
   
(fa)1,2 
  
2x 
(ED50)2 
 
(fa)2 
    
(fa)1,2 
 
4x 
(ED50)2 
 
(fa)2 
     
(fa)1,2 
 
 
 
Because the ratio is constant, each mixture can be treated as a single agent to obtain 
the Dm (median effect dose or concentration – ED50, IC50 or LD50 or TD50 if 
appropriate), m parameter (exponent signifying the sigmoidicity i.e. shape of the 
dose-effect curve), construct an automated Fa-CI (fraction affected-combination 
index) table and plot classic and conservative isobolograms. 
 
In situations where the ratios are random or arbitrary or one concentration changes 
and the other is fixed, CalcuSyn can still be used to calculate combination index (CI) 
values for each data point provided the m and Dm parameters for each single agent 
are available. Fa-CI plot simulations are not available, although the combination data 
plots can be placed on the Fa-CI plot 
 
Broadly speaking, a CI value of 1 is additive, < 1 is synergistic and > 1 is 
antagonistic. This is rather over simplified and the CalcuSyn authors suggest the 
following: 
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Range of CI   Symbol  Description   
<0.1    + + + + +  very strong synergism 
0.1-0.3    + + + +  strong synergism 
0.3-0.7    + + +   synergism 
0.7-0.85   + +   moderate synergism 
0.85-0.90   +   slight synergism 
0.90-1.10   +/-   nearly additive 
1.10-1.20   -   slight antagonism 
1.20-1.45   - -   moderate antagonism 
1.45-3.3   - - -    antagonism 
3.3-10    - - - -    strong antagonism 
>10    - - - - -   very strong antagonism 
 
 
2.1.7 In vitro synergy assay 
The effect of the combination of reovirus and rapamycin on cell proliferation was 
assessed by calculating combination-index (CI) values using CalcuSyn software 
(Biosoft, Ferguson, MO). Experiments were performed as described for the in vitro 
survival assay with 7.5 x 10
3
 cells being plated on 96-well plates and allowed to 
adhere overnight. The cells were treated with 4, 2, 1, 0.5 and 0.25 times the calculated 
median effective dose (ED50) of each agent in a constant ratio checkerboard design. 
After 48 hours cell viability was assessed using the MTS assay as described 
previously. The effect of each dose level was entered into the CalcuSyn programme 
and isobolograms and combination indices generated. 
2.2 Western Blotting 
2.2.1 Lysate Preparation 
The cells of interest were plated onto 6-well plates at a density of 500,000 cells per 
well, aiming for 75% confluency at 24 hours. After incubating overnight, the cells 
were exposed to the condition of interest and returned to the incubator for a further 24 
hours. The cells were then washed twice with cold PBS and subsequently cold RIPA 
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buffer (500µl/10ml culture volume) containing 10µl/ml each of protease inhibitor 
cocktail, phosphatase inhibitor cocktail and EDTA was added (Perbio Science, UK). 
The 6-well plate was placed on ice for 5 minutes and occasionally swirled to mix. The 
cell and buffer mixture was collected into 1.5ml tubes using a cell-scraper and sheared 
with a 21-gauge needle and syringe. The tubes containing the lysate were then placed 
in an ultrasonic waterbath for 30 seconds to 1 minute to decrease the viscosity. The 
lysates were stored at -80°C until required. 
 
2.2.2 Protein Concentration Estimation 
To determine the concentration of protein in each lysate and thereby enable accurate 
loading of samples for western blot analysis, the Pierce BCA protein assay (Thermo 
Scientific) was used. Briefly, serial dilutions of a protein standard were prepared and 
251 of each standard or lysate was pipetted into a 96-well plate. 200 l of the 
working reagent was then added to each well and the plate was mixed thoroughly on a 
plate shaker for 30 seconds. The plate was covered and incubated at 37°C for 30 
minutes. After cooling the plate to room temperature, the absorbance was measured at 
562nm on a Beckmann coulter plate reader. The average 562 nm absorbance 
measurement of the blank standard replicates were subtracted from the 562 nm 
measurements of all other individual standard and unknown sample replicates and a 
standard curve was plotted. This curve was then used to determine the protein 
concentration of each lysate sample. 
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2.2.3 Western Blot Procedure 
Lysates were thawed in a 37°C waterbath and then 10g, as determined by BCA 
assay, was transferred to new 1.5ml tube and sample buffer (1:4) and reducing agent 
(1:10) added at the ratios indicated. The samples were heated at 70°C for 10 minutes, 
transferred to ice for 2 minutes, vortexed briefly, and then centrifuged for 30 seconds. 
MOPS running buffer was prepared and the samples were loaded into an Invitrogen 
NuPage Novex 10% acrylamide Bis-Tris gels. The gel was run at 200 Volts for 1 
hour. 
For transfer, a pvdf membrane was wetted in methanol for 2 minutes before being 
soaked in transfer buffer along with blotting paper and transfer pads for a further 3 
minutes. A sandwich was then assembled containing gel, pvdf membrane, blotting 
paper and pads, placed in cathode core and the anode core placed on top. Having been 
placed in the transfer tank this was then filled with transfer buffer and run at 30 Volts 
for 2 hours. After transfer, the membrane was removed from the sandwich and 
washed in TBS 0.1%Tween then placed in 5% milk in TBS-0.1%Tween to block for 
2hr at RT with rocking. The primary antibody was diluted in TBS-0.1%Tween, the 
membrane added and incubated overnight at 4°C with gentle shaking. The membrane 
was then washed 3 x 5 minutes in TBS-0.1%Tween, secondary antibody added and 
allowed to incubate for 1 hour at room temperature. After further washing, ECL 
detection reagent was added to the membrane, incubated for 1 minute, exposed to 
photographic film for 1-5 minutes and developed. 
If further stains were to be performed on the membrane then it is washed in TBS-
0.1%Tween and added to 15mls of stripping buffer for 15 minutes. After a further 
wash, the membrane is re-blocked and the same protocol followed as before. 
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2.2.4 Antibodies 
Epidermal Growth Factor Receptor (EGFR) antibody (ab52894) and beta Actin 
antibody (ab8227) were obtained from Abcam (Cambridge, UK). Phospho-EGFR 
antibody Tyr992 and Tyr1173 (CST2235 and CST4407), S6K, phosphorylated-eIF2, 
phospho-4E-BP1 antibody Thr37/46 (CST2855), Akt antibody (CST 9271), and 
phospho-Akt antibody Ser473 (CST9271) were obtained from Cell Signaling 
Technology / New England Biolabs. Phospho-EGFR Tyr1068 (44788G) was obtained 
from Invitrogen (Paisley, UK). 
 
2.3 Quantitative Polymerase Chain Reaction (Q-PCR) 
2.3.1 RNA extraction 
Cells were seeded on a 6-well plate at a concentration of 500,000 cells per well and 
incubated overnight at 37
o
C. Reovirus was then added at IC50 of that particular cell 
line as determined previously from cell viability assays. The plates were incubated at 
37
o
C for a further 24 hours before the RNA was extracted. 
RNA extraction was performed using Qiagen RNeasy Plus Kit. Prior to starting, 10l 
of 6-mercaptoethanol was added for every 1ml of buffer RLT Plus used. Cell culture 
medium was aspirated from wells and replaced with 500l buffer RLT Plus. The 
lysate was homogenized by passing at least 5 times through a 21-gauge needle. 
350l of the lysate was transferred to gDNA Eliminator spin column placed in a 2ml 
collection tube and centrifuged for 1 minute at 10,000rpm. The column was discarded 
and 350l of 70% ethanol added to the flow through. 700l of the sample was then 
transferred to an RNeasy spin column placed in a 2ml collection tube and centrifuged 
for 1 minute a 10,000rpm. The flow through was discarded and 700l of buffer RW1 
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added to the RNeasy spin column and centrifuged at 10,000rpm for 1 minute. The 
flow through was discarded and 500l of buffer RPE added to the spin column and 
centrifuged for a further minute. This last step was repeated except this time the 
column was centrifuged for 2 minutes. The RNeasy spin column was placed in a new 
2ml collection tube and centrifuged at full speed for 1 minute. The spin column was 
then placed in a 1.5ml collection tube and 50l of RNase-free water added directly to 
the column membrane. This was then centrifuged for 1 minute at 10,000rpm to elute 
the RNA. The RNA was quantified using Nano-drop spectrophotometer and stored at 
-80°C. 
 
2.3.2 cDNA formation and Q-PCR 
RNA was reverse-transcribed as described previously. Briefly, RNA was first 
denatured by heating to 65°C for 5 min. One to five micrograms of RNA was 
incubated in a volume of 50L at 50°C for 1 h with final concentrations of 10 mmol/L 
of DTT, 1 mmol/L of deoxynucleotide triphosphate mix, as well as 100 g/L of 
poly-T primers, 200 units of reverse transcriptase (Invitrogen), and 40 units of 
RNaseOUT (Invitrogen). The cDNA synthesis reaction was terminated by placing 
tubes at 85°C for 5 min. 180l of water was added to each cDNA sample and 5l of 
cDNA was added for a Q-PCR. 
 
Quantitative reverse transcription-PCR was done using the Stratagene MX4000 real-
time PCR machine. The Stratagene MX4000Note: measures PCR product 
accumulation during the exponential phase of the reaction, prior to the amplification 
becoming vulnerable to limited reagents and cycling variability. Fluorescence 
increases in accordance with increasing levels of PCR product. 5l of cDNA was 
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added to 1l of primer mix, 6.5l of water and 12.5l of SYBR green and run in the 
PCR machine. Mouse and human EGFR primers were obtained from Eurogentec as 
follows: mmEGFR Fw 5’-CAGTGGGCAACCCTGAGTAT-3’; mmEGFR Rev 5’- 
GGGCCCTTAAATATGCCATT-3’; hmEGFR Fw 5’-CAGCGCTACCTTGTCAT 
TCA-3’; and hmEGFR Rev 5’-TGCACTCAGAGAGCTCAGGA-3’.  
 
2.4 Viral Plaque Assay 
 
25cm
2
 flasks were seeded with 5 x 10
5
 cells in 5ml of medium and incubated 
overnight at 37
o
C. The medium was removed from the flask and replaced with 5ml 
medium + 2% FCS with either reovirus, or reovirus and rapamycin, added. The flasks 
were then incubated for 48 or 72 hours, after which time they were transferred to a     
-80
o
C freezer. The flasks were then removed from the freezer, allowed to thaw and 
returned to the freezer. This process was repeated to ensure complete lysis of the cells. 
6-well plates were seeded with 1 x 10
6
 L929 cells in each well with one plate per 
condition. The plates were incubated overnight at 37
 o
C. The flasks were thawed once 
more and the contents transferred to a centrifuge tube. To pellet the cellular contents 
the tubes were centrifuged for 10 minutes at 1400 x g. A dilution series was then 
performed by taking 150l of the supernatant and adding it to 1350l of medium. 
This step was repeated to give a range of 10
-1
 to 10
 -9
. The medium was removed from 
the L929 cells and replaced with 1ml of the diluted virus from 10
-4
 to 10
-9
. The virus 
was allowed to adsorb for 3 hours with the plate occasionally being rocked to ensure 
the monolayer was entirely covered.  
The overlay was prepared by melting pre-autoclaved 2% SeaPlaque agarose (Lorum) 
in a microwave and allowing to cool before mixing with an equal volume of 2 x MEM 
 60 
at 37
 o
C. The transfection medium was removed from each well and 2ml of the 
overlay added to each well, letting the agar run gently down the side of the well. The 
agar was allowed to set completely at room temperature before transferring the plates 
to 37
o
C incubator for three days. 
The overlays were stained with 0.5ml neutral red solution diluted in 1:10 PBS (from 
0.33% stock solution). The plates were returned to the incubator for 3 hours. Plaques 
were counted in all wells of dilutions giving between 2 and 50 plaques/well. From this 
the number of plaques/ml and pfu/input cell could be calculated 
 
2.5 Apoptosis Assays 
2.5.1 Annexin V / PI Assay 
 
A 6-well plate was seeded with 2 x 10
5
 cells per well in 2ml and incubated overnight 
at 37
 o
C. The medium was removed and replaced with 2ml fresh medium with 2% 
FCS either alone or with reovirus, rapamycin, or a combination either given 
concomitantly or in sequence. The plates were returned to the incubator and left for 
48 to 72 hours. At the time point of interest the medium was removed from each well 
and transferred to a centrifuge tube. The cells were trypsinised, added to their 
respective medium and centrifuged. The cells were then resuspended in 50l of 
binding buffer, and 4l of Annexin and 4l of Propidium Iodide stains added to each 
sample. The samples were incubated at room temperature in the dark for 15 minutes 
before being analysed on a Coulter Epics XL flow cytometer (Beckman Coulter)
 
using EXPO32 ADC software (Beckman Coulter). 
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2.5.2 Caspase 3/7 Assay 
 
Estimation of Caspase 3 and 7 was undertaken using CaspaseGlo Assay (Promega). 
96-well plates were used to seed 7.5 x 10
3
 cells in 100l of medium per well and the 
plate was incubated overnight at 37
 o
C. The cells were either treated with medium + 
2% FCS (control), rapamycin 10nM, reovirus 10MOI, or a combination of reovirus 
and rapamycin either given concomitantly or rapamycin given 24 hours before or after 
the reovirus. The plates were incubated for 48 or 72 hours. At the time point of 
interest 100l of CaspaseGlo was added to each well and the plate shaken to ensure 
adequate mixing. The plate was incubated at room temperature for 1 hour and then the 
luminescence measured at 565nM using a Beckman Coulter plate reader.  
 
 
2.6 Autophagy Assay 
Cells undergoing autophagy form multiple cytoplasmic acidic vacuoles that can be 
detected using the vital stain acridine orange. In normal cells the cytoplasm fluoresces 
green when stained with acridine orange and viewed with a UV light. However, the 
acidic component of the vacuoles seen in autophagy fluoresces red.  
6-well plates were seeded with 5 x 10
5
 cells per well 24 hours prior to treatment. The 
cells were then treated with either medium with 10% FCS, medium 2% FCS, 10M 
rapamycin, 10nM rapamycin, reovirus MOI 10, or a combination of rapamycin 10nM 
and reovirus MOI 10 either concomitantly or in sequence. 48 hours later acridine 
orange was added directly to the treatment/infection media at a final concetration of 
1g/ml. After incubating for 15 minutes, the supernatant was removed and kept, and 
the monolayer washed once with PBS. The cells were trypsinised, added to their 
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respective supernatant and centrifuged. The resulting supernatant was discarded and 
the cell pellet resuspended in 1ml of phenol red free D-MEM + 1% FCS. The cells 
were then analysed using FACS. 
 
2.7 Transfection of human prostate cancer cells with EGFR siRNA 
Transfection of siRNA into PC3 and DU145 cells was carried out using the Silencer 
siRNA starter Kit (Ambion). This technology uses reverse transfection, where the 
cells are transfected as they adhere to the plate after trypsinisation. 
First, transfection optimisation was performed using GAPDH siRNA and assessing 
the degree of GAPDH knockdown using different concentrations of transfection 
reagent and numbers of cells. This kit uses a colorimetric endpoint to determine the 
degree of GAPDH knockdown. Once the optimum concentration of transfection 
reagent and number of cells had been established (6μl/well of transfection reagent and 
1.2 x 10
5
 cells/well for both PC3 and DU145), cells were added to the wells of a 6-
well plate containing transfection reagent and one of the following: Silencer select 
validated EGFR siRNA, negative control siRNA, and medium. Three different 
siRNAs were assessed: s563, s564, and s565. A replicate plate was seeded at the same 
time for subsequent experiments. The cells were incubated for 24 hours and the media 
in the wells replaced by normal growth media. After a further 24 hours incubation, the 
cells from one plate were used to assess degree of EGFR knockdown by qPCR and 
the cells from the other plate were transferred to a 96-well plate and infected with 
reovirus as per MTS assay protocol in chapter 2.1.5. 
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2.8 Microarray analysis 
Total RNA was extracted from test cells using the Qiagen RNeasy mini kit (Qiagen 
Inc) according to the manufacturer’s recommendations. Fluorescent-labeled cRNA 
was produced using the One-Color Low RNA Input Linear Amp Kit (Agilent 
Technologies UK Ltd) and purified using RNeasy Mini Kit (Qiagen). The labelled 
cRNA was fragmented and hybridized overnight to Whole Mouse Genome (4x44K) 
Oligo Microarray slides (Agilent) using the Agilent Gene expression Hybridization 
Kit (Agilent). The slides were washed and scanned using an Agilent DNA Microarray 
Scanner (Agilent). Data was extracted using the Agilent Feature Extraction software 
and was subsequently analysed using GeneSpring GX 7.3.1 (Agilent), using the fold 
change of each gene based upon normalised data. Only changes calculated to be 
significant (p<0.05) are included in the results. 
2.9 Cell cycle analysis of B16.F10 cells exposed to reovirus and/or rapamycin 
Following overnight incubation, B16.F10 cells were infected with reovirus at 
multiplicities of infection (MOI) of 10 and 10 nM Rapamycin (Sigma). The treated 
B16.F10 cells were trypsinised and washed in ice cold PBS. The cells were 
centrifuged at 1500 rpm at 4
0
C for 3 min and resuspended in 300 l of ice cold 50% 
FCS/PBS. 900 μl of ice cold 70% ethanol was added drop wise during vortexing. The 
resulting cell suspension was incubated overnight at 4
0
C. The cells were washed twice 
with ice cold PBS cells. The pellet was resuspended in 200 μl of 5 µg/ml propidium 
iodide and 1 mg/ml ribonuclease and incubated at 37
0
C for 30 min in the dark. 
Analysis was carried out by flow cytometry using a MACSQuant Analyser (Miltenyi 
Biotech, Bergisch Gladbach, Germany) and MACSQuantify software (Miltenyi 
Biotech). 
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2.10 In vivo studies 
All procedures were approved by United Kingdom Home Office and institutional 
boards. All animal experiments were repeated at least three times. C57Bl/6 mice were 
purchased from B and K Universal Ltd. B16.F10 cells were harvested using 100% 
(v/v) trypsin in versene at 37C. The cells were then centrifuged at 1200g for 5 
minutes at 4C and resuspended in PBS. The cells were then counted and finally 
resuspended at 5 x 10
6
 cells/ml in PBS.  
 
 Subcutaneous tumours were established in the flank of each mouse by injecting 5 x 
10
5
 cells in a volume of 100µL Hanks Balanced Salt Solution (HBSS; Sigma). 
Animals were examined thrice weekly for tumour development. Three orthogonal 
tumour diameters (d1, d2, and
 
d3) were measured using Vernier callipers and tumour
 
volume was calculated from the formula V = π/6 d1·d2·d3. Animals were killed when 
tumour size exceeded 15mm in any one dimension.  
 
Once tumours were established, (average tumour diameter 4.5-5.5mm, approximately 
10-12 days for B16.F10), mice were randomly assigned to treatment groups and 
treated on days 1 and 4 with either reovirus or rapamycin alone or as a combined 
therapy. Reovirus (1 x 10
8
 pfu in 100µL volume) was administered using a single 
cutaneous puncture site. Once in a subcutaneous
 
location, the 25-gauge needle was 
redirected along multiple
 
tracks within the tumour to achieve maximal dispersal of the
 
reovirus. By careful application of this technique, it was possible
 
to achieve direct 
intratumoral injection without backflow of
 
the injectate. Rapamycin 5mg/kg was 
administered intraperitoneally in a total volume of 100µL. Control animals received 
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an equivalent volume of HBSS alone, administered in an identical manner. For the 
sequence experiments a further group was added where mice were treated on day 1 
and 4 with reovirus and then day 2 and 5 with rapamycin. All groups who received 
rapamycin had a further two treatments of rapamycin the following week on day 8 
and 12.  
2.11 In vivo tumour and organ viral retrieval  
In order to assess the effect of rapamycin on viral titre in vivo, virus levels in the 
tumour, lungs, liver and heart of mice treated with reovirus, reovirus / rapamycin 
concomitantly and rapamycin administered 24h post reovirus were determined using 
plaque assay. 
Flank tumours were established in C57Bl/6 mice as described above. Ten days after 
tumour implantation the tumours were injected with reovirus. There were four groups 
in total with six animals in each group: reovirus only, reovirus and rapamycin 
concomitantly, reovirus followed by rapamycin and a control group that just received 
a dummy injection of Hanks Solution. 
Forty-eight hours after the reovirus injection the mice were sacrificed and their 
tumour, liver, lungs and heart harvested and weighed. These were stored at -80
o
C in 
sterile 2ml Eppendorf tubes before being and homogenized in a TissueLyser (Qiagen) 
at 30Hz for 2 minutes. The samples were centrifuged at 4000g for 10 minutes to 
remove all cellular debris and the supernatant kept. Dilution series of the supernatant 
were prepared from 10
-1
 to 10
-9
. These dilutions were then added to pre-prepared 
L929 mouse fibroblast monolayers in duplicate as described earlier. After 3 hours 
transfection, the medium was removed from the monolayer and overlayed by agarose. 
The plates were read at 3 days using neutral red stain. An average of the pfu/ml and 
pfu/g was calculated. 
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2.12 In vivo detection of neutralizing antireoviral antibodies 
To determine the effect of rapamycin on the immune response to reovirus infection in 
vivo, antibody levels were measured at baseline and 9 days after the first exposure to 
reovirus using a modified neutralizing antibody assay. The effect of mouse serum 
samples on the ability of reovirus to kill a monolayer of target mouse L929 cells was 
determined as described previously
83
.  
 
Briefly, there were four treatment groups with five animals per group: A) control, B) 
reovirus, C) sequential reovirus then rapamycin and D) concomitant reovirus and 
rapamycin. Reovirus 1 x 10
8 
pfu was given to all animals on day 1 and day 4. 
Rapamycin, 5mg/kg, was given at the same time as the reovirus in the concomitant 
group and 24 hours after reovirus in the sequential group. A further dose of rapamycin 
was given on day 8 in both concomitant and sequential groups. Serum samples were 
taken from each animal at baseline and when mice were sacrificed on day 9, batched 
and analyzed simultaneously. To determine a suitable virus dilution for subsequent 
assay, L929 cells were plated in 96-well plates at 2.5 x 10
4
 cells/well and incubated 
overnight at 37
o
C and 5% CO2. Reovirus stock (3.5 x 10
10
/ml) was added in two 
dilution series (2-fold and 10-fold) across the plate such that the final dilutions of the 
two series were 1:32,768 and 1:10
12
. After 2 hours, the reovirus inoculum was 
removed and replaced with growth medium. After a further 48 hours, cell survival 
was measured by MTT assay. In order to establish a suitable dilution series for the 
estimation of neutralizing antibody levels in the serum, the above experiment was 
repeated with a constant titre of reovirus (known to cause 80% cell death) that was 
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pre-incubated with a dilution series of goat polyclonal anti-reoviral antibody and cell 
survival was measured at 48 hours by MTT assay.  
 
2.13 Statistics 
Comparisons between groups were done using the t test, 1-way ANOVA with 
Bonferroni multiple comparison tests, and 2-way ANOVA, with Bonferroni post-
tests. Survival curves were estimated using the Kaplan-Meier method, with 
significance being assessed using the log-rank test. Statistical analysis was performed 
using GraphPad Prism 5 (GraphPad Software Inc.).  
 
2.14 Phase I Clinical Trial 
2.14.1 Patients 
Patients diagnosed with advanced or metastatic solid tumours refractory to standard 
therapy, or for which no curative standard therapy exists, and for whom docetaxel was 
an appropriate palliative chemotherapy, were considered for enrolment. To be eligible 
patients were required to have measurable or evaluable disease; no continuing 
residual toxic effects related to any prior anti-cancer therapy, with any such effect 
having resolved to Grade 1 or lower; be ≥18 years of age; received no chemotherapy, 
radiotherapy, biological therapy and hormone therapy (apart from patients with breast 
cancer and LHRH analogues in prostate cancer) within 28 days prior to receiving the 
study drug; an ECOG Performance score of ≤2 and a life expectancy of at least 3 
months .  
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The following baseline laboratory results were required: absolute neutrophil count 
≥1,500/μl, platelets ≥100,000/μl, haemoglobin ≥9.0mg/dL, serum creatinine ≤1.5 x 
institutional upper limit of normal, total bilirubin ≤1.5 x institutional upper limit of 
normal, aspartate transaminase / alanine transaminase ≤2.5 x institutional upper limit 
of normal; and a negative pregnancy test for females of childbearing potential. 
Exclusion criteria included known brain metastases, concurrent immunosuppressive 
therapy, known HIV, hepatitis B or C infections, pregnancy or breast-feeding, 
clinically significant cardiac disease (New York Heart Association class III or IV), 
and dementia or altered mental state that would prohibit informed consent. The study 
was approved by the local ethics committees. 
2.14.2 Study Design 
This was an open-label, dose-escalating, non-randomised, three-centre Phase I study 
of reolysin given intravenously combined with docetaxel every 3 weeks. Docetaxel, 
following premedication with dexamethasone, was given as a 60 minute iv infusion 
on day 1, every 21 days. Reolysin was administered to the patients as iv infusion over 
60 minutes from day 1 to day 5, every 21 days. On day 1 of each cycle, when both 
agents were to be given, the docetaxel was given first. Three patients were enrolled in 
each cohort, at the dose level shown in the table 2.1, in order to determine the 
maximum tolerated dose. At the beginning of each new dose level only one patient 
was treated. The second and third patient of the cohort were not treated for at least 2 
weeks after the initial patient in that cohort had received the first dose of reolysin. 
Patients continued to receive treatment under this protocol for a maximum of eight 
cycles, provided there was no evidence of disease progression and the treatment was 
tolerated. 
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Table 2.1  Dose level by cohort  
Cohort # Patients 
Reovirus dose 
(TCID50) 
Number 
of Days 
Docetaxel 
dose (mg/m
2
) 
- 1∗ - 1x10
9
 5 75 
+1 3 3x109 5 75 
+2 3 1x1010 5 75 
+3 3 3x1010 5 75 
* Necessary only if toxicity is encountered at the initial dose level.  
 
 
2.14.3 Dose Escalation 
Patients were initially enrolled in groups of three and individually assessed for safety 
and dose limiting toxicities. Patients were considered evaluable for dose escalation 
decisions if they had received at least one cycle or withdrew from the study due to 
drug-related toxicity. If a patient withdrew from the study without meeting these 
criteria they were replaced in the cohort.  
 
If one out of three patients in a dose group experienced a DLT during the first cycle, 
three more patients were added to that dose group. If two or more patients in a dose 
group experience a DLT during the first cycle, the previous lower dose would be 
defined as the MTD. Intra-patient dose escalations were not permitted. Treatment was 
continued for a maximum of eight cycles, provided it was well tolerated and there was 
no evidence of disease progression. 
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2.14.4 Viral administration 
Reolysin was supplied by Oncolytics Biotech in single-use 1mL glass vials containing 
a frozen viral suspension in PBS. Stock was stored at -70°C and thawed rapidly over 
2 min, and the appropriate TCID50 dose was diluted to 250mL in 0.9% sodium 
chloride and infused over 1 hour through a peripheral line. Treatment was given in a 
side-room and patients were monitored closely (including blood pressure, 
temperature, and heart rate measurements) during, and for at least one hour after 
infusion.  
 
2.14.5 Dose Limiting Toxicity 
Toxicities were graded according to Common Terminology Criteria for Adverse 
Events version 3.0. DLT was defined as any of the following events that were 
determined to be possibly or probably related to combination therapy during the first 
cycle of treatment irrespective of whether the toxicity had resolved: absolute 
neutrophil count <0.5 x 10
9
 lasting for more than 7 days or with sepsis, platelet count 
<25 x 10
9
/L, grade 2 neurotoxicity or cardiotoxicity, any other drug-related non-
haematological grade 3/4 toxicity, with the exceptions of flu-like symptoms, nausea 
and vomiting if appropriate prophylactic or therapeutic measures had not been 
administered, and the inability to tolerate one course of therapy due to toxicity. 
 
In order to define DLT, patients were not given prophylactic growth factor support, 
antidiarrhoeals, or antipyretics during the first cycle of therapy.  
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2.14.6 Safety Evaluations 
Safety was assessed by the evaluation of the type, frequency, and severity of adverse 
events, changes in clinical laboratory tests (including haematological, clinical 
chemistry and urinalysis), immunogenicity and physical examination. ECG was 
performed at baseline, after each reolysin infusion for the first cycle, on day 1 of each 
subsequent cycle and at the end of the study. Patients experiencing any DLT in any 
cycle had their treatment held until toxicity resolved to baseline or grade 1. Upon 
resolution, reolysin and docetaxel therapy was recommenced at a lower dose level. 
 
2.14.7 Response Evaluation 
Response was assessed by RECIST criteria
112
. All patients were clinically evaluated 
after each course of treatment and radiologically every second course until there was 
evidence of progressive disease. Tumour markers were also used to assess response in 
appropriate patients. 
 
2.14.8 Pharmacokinetic and Pharmacodynamic endpoints 
To assess docetaxel pharmacokinetics blood samples were taken during the first cycle 
of treatment at the following time points: baseline, 15 minutes, 30 minutes, 1 hour, 
2h, 4h, 6h, 8h, 24h, and 48h. Three patients whose tumours were accessible 
underwent biopsy to evaluate viral replication. Samples were stored at -80°C until the 
time of analysis. At this time, the biopsies were thawed and macerated in 1 mL 
DMEM and centrifuged at 3,600 rpm for 5 minutes. The supernatant was taken, 
serially diluted (1:10), and placed on to L929 cells in quadruplicates in a 96-well 
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plate. The viral titre was calculated using the Kärber statistical method for a standard 
TCID50 assay.  
 
2.14.9 Analysis of Viral Shedding by reverse transcription-PCR 
Initial evaluation of the detection limit of reovirus RNA by 35 cycles of reverse 
transcription-PCR (RT-PCR) was done. Viral RNA was extracted from 140μL stock 
using the QIAamp viral RNA mini-kit (Qiagen) and serially diluted.  5μL was assayed 
directly by RT-PCR using the One-Step RT-PCR Enzyme Mix Kit (Qiagen). Reovirus 
s3 cDNA targeted primers used were forward 5´-GGGCTGCACATTACCACTGA 
and reverse 5´-CTCCTCGCAATACAACTCGT. PCR conditions were 50°C for 30 
min, for reverse transcription; 95°C for 15 min; and 35 cycles of 95°C for 30 seconds, 
62°C for 45 s, and 72°C for 45 s followed by 72°C for 7 min.  
All patients had blood samples collected for the detection of reovirus titres during the 
first 2 cycles. Samples were taken at baseline, 4 hours after the last dose of reovirus 
on day 5 and day 15. Blood from the contra-lateral arm was collected into EDTA 
tubes, centrifuged at 1,200 x g for 10 min at 4°C, and stored at -70°C. Urine, sputum, 
and faecal swab (after PBS elution) samples were also stored at -70°C. Samples were 
analyzed after the last treatment dose in each cycle and weekly using the 35-cycle RT-
PCR. Reovirus RNA (300-bp PCR product) and water were included in all 
experiments as positive and negative controls, respectively. 
 
2.14.10  Detection of neutralizing antireoviral antibodies 
A modified neutralizing antibody assay was used to detect antibody titres at baseline 
and weekly during the first 2 cycles of treatment by measuring the effect of patient 
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serum samples on the ability of reovirus to kill a monolayer of target mouse L929 
cells
83
. The neutralizing antireoviral antibodies (NARA) titre of serum samples was 
expressed as the last dilution causing <80% cell killing as described previously
113
. 
Assays were performed in duplicate by 2 different technicians to verify the results. 
 
2.14.11  Immunohistochemistry of biopsies for reoviral protein 
Where possible, fine needle core biopsies were taken from accessible metastatic sites 
after reovirus and taxotere treatment, on day 5 of cycle 2. Biopsies were fixed in 
formalin and paraffin embedded. Immunohistochemical analysis of reovirus protein 
expression in 5 micron sections followed a published protocol
114
.  The Benchmark LT 
automated system (Ventana Medical Systems, Tucson, AZ) was used.  In brief, 
optimal conditions were determined from blinded analysis of cells either infected with 
reovirus or not infected using 1:3000 diluted primary antibody following pretreatment 
in Ventana’s cell conditioning 1 for 30 minutes (antigen retrieval).  The primary 
antibody was a kind gift from Dr. Matt Coffey and was derived in goat; a rabbit 
antigoat (ABCAM, Massachusetts) secondary antibody was used at a dilution of 
1:3000.  The antigen was detected with the Ultraview Universal DAB or Fast Red 
system from Ventana with a counterstain of hematoxylin.  The negative controls 
included omission of the primary antibody and carcinomas from patients who had not 
been treated with the reovirus.  
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Rapamycin 
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3.1 Introduction 
3.1.1 mTOR Inhibitors 
The discovery of the mammalian target of rapamycin (mTOR) proteins was through 
the study of a natural product. Researchers studying the bacterium Streptomyces 
hygroscopicus, obtained from a soil sample from Easter Island, isolated a lipophilic 
molecule they called rapamycin
115
. Initially developed as an antifungal, it was 
discovered to have immunosuppressive properties and then later shown to have 
powerful antiproliferative effects on human tumour cells
116
. It was not until twenty 
years after its discovery that its mechanism of action was elucidated. 
 
Using the budding yeast Saccharomyces cerevisiae, which are sensitive to the growth 
inhibitory effects of rapamycin, researchers generated a series of rapamycin-resistant 
mutants. This led to the discovery that the expression of a cytoplasmic immunophilin 
receptor, called FK506BP12, was required for cell growth inhibition by rapamycin 
and that mutations in either of two new genes, Tor1 and Tor2, conferred resistance to 
rapamycin
117
. Though the two Tor genes are largely homologous they are not 
functionally redundant: loss of Tor1 causes slow growth whereas loss of Tor2 is lethal 
to these yeast cells. These findings led to studies in mammalian cells that ultimately 
allowed the purification of a high molecular mass protein now know as mTOR
118
.   
 
Rapamycin and its analogues bind FK506 binding protein, which in turn binds to 
mTOR leading to the inhibition of downstream signalling. Rapamycin causes cell 
cycle arrest in tumour cells, but also inhibits endothelial cell proliferation, HIF-1 and 
VEGF expression, angiogenesis, and vascular permeability
119,120
.  These vascular 
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effects of mTOR inhibitors, together with their direct anti-tumour and 
immunosuppressive effects, demonstrate the potential of these drugs as anticancer 
agents and suggest possible mechanisms for synergy between other anticancer drugs 
including oncolytic viruses.   
 
  
3.1.2 Structure and Signalling Complexes of mTOR 
The mTOR proteins are members of the phosphoinositide 3-kinase-related kinases 
and are an integral component of the PI3K/Akt signalling pathway
121
. This pathway 
transmits signals related to cell proliferation as well as being involved in stress 
responses. mTOR is a 289kDa serine-threonine kinase that lies downstream of Akt in 
this pathway. The best known function of mTOR is the regulation of translation 
initiation which it achieves largely by phosphorylating, and thereby inactivating, the 
translation suppressor eukaryotic initiation factor 4E-binding protein 1(4E-BP1), and 
also activating ribosomal p70 S6 kinase (S6K1). This leads to the translation of a 
group of mRNAs whose protein products are necessary for passage through the G1 
phase of the cell cycle. 
 
mTOR activity is regulated by PI3K/Akt
122
. In turn, PI3K is activated as a result of 
the ligand-dependent activation of tyrosine kinase receptors, G-protein-coupled 
receptors, or integrins. Activation can also be receptor independent if for example a 
cell has a constitutively active Ras pathway
123
. Activated PI3K catalyses the 
conversion of PIP2 to PIP3, which in turn phosphorylates Akt. This results in the 
phophorylation of numerous other proteins that affect cell growth, cell survival, and 
regulate the cell cycle. mTOR exists in two multiprotein complexes: mTORC1 and 
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mTORC2 which have distinct signalling properties
124
. mTORC1 is made up of 
mTOR, raptor and mammalian LST8
125
, and leads to phosphorylation of 4EBP-1 and 
S6K1. mTORC2 consists of mTOR, rictor and mammalian  LST8, and directly 
phosphorylates Akt
126
.  
 
Growth factor signalling as well as nutrients and energy status regulate mTOR 
signalling. Our understanding of the complex regulation of mTOR has been increased 
with the discovery that the tuberous sclerosis complex (TSC) is a modulator between 
Akt and mTOR
127
. In the non-stimulated state, TSC binds and inhibits mTOR. Stimuli 
activating Akt can directly phosphorylate TSC2, stopping its binding to TSC1 and 
consequently leading to an increase in mTOR kinase activity
128
.  TSC2 contains a 
GTPase activating domain that inactivates Rheb, which associates with and directly 
activates mTORC1. It has been shown that Ras/MAPK signalling also inhibits 
TSC2
129
.  Low cellular energy stores are also thought to activate TSC2 via AMPK, 
inhibiting mTOR and thus reducing protein synthesis. A simplified diagram of the 
Akt / mTOR pathway is shown in figure 3.1. 
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Figure 3.1 mTOR Pathway 
Nutrients as well as growth factors stimulate the PI3K / Akt pathway of which mTOR 
is a critical component. Arrows represent activation and bars represent inhibition. The 
main effects of mTORC1 activation are highlighted in green. The negative feedback 
loop from S6K1 to IRS1 is shown on the left.  
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mTORC1 is sensitive to rapamycin, and treatment with rapamycin reduces the 
phosphorylation of 4EBP1 and S6K1. mTORC2 on the other hand was thought to be 
insensitive to rapamycin
130
, but rapamycin does regulate rictor phosphorylation
131
, 
and high doses or prolonged treatment with rapamycin can reduce mTORC2 levels in 
some cell lines
132
.  
 
In some cell lines rapamycin induces Akt activation
133
. Insulin-like growth factor-1 
(IGF-1) stimulation of the PI3K/Akt pathway leads to a negative feedback loop due to 
S6K-mediated degradation of IRS-1. It is thought that the Akt activation seen with 
rapamycin maybe as a result of the loss of this feedback loop
134
. The effect of 
rapamycin on Akt varies with cell line, but also with drug dose, with lower doses 
leading to an increase in Akt activation and higher doses reducing Akt activity
135
. 
 
3.1.3 Clinical Data 
Current mTOR inhibitors in clinical trials include rapamycin / Sirolimus (Wyeth), 
CCI-779 / Temsirolimus (Wyeth), RAD-001 / Everolimus (Novartis) and AP23573 
(Ariad). Despite the central role that mTOR plays in a wide variety of cellular 
processes, these agents are reasonably well tolerated. Most toxicities appear to be 
dose dependent and include: fatigue, mucositis, nausea, diarrhoea, cutaneous toxicity, 
hypercholesterolaemia, hyperglycaemia, deranged liver function and pneumonitis
136
.  
 
mTOR inhibition now has a definitive place in the treatment of metastatic renal cell 
carcinoma following a phase III trial of temsirolimus
137
. This trial compared the use 
of single agent temsirolimus, or interferon, or a combination, in patients with poor 
prognosis metastatic renal cell carcinoma. Patients who received single agent 
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temsirolimus had a significantly longer overall survival (OS) when compared with 
interferon, or combination (11, 7.3 and 8.4 months respectively). Similarly, a double-
blind, phase III, randomised control trial of everolimus in patients with metastatic 
renal cell carcinoma who had progressed on VEGF inhibitors showed a significant 
increase in progression-free survival (PFS) and was halted early
138
. The probability of 
being progression-free at 6 months was 26% for everolimus and 2% for placebo. 
 
mTOR inhibitors have been evaluated in a range of other cancer types including 
lymphoma, breast cancer, sarcoma, melanoma, and endometrial cancer. A phase III 
trial of temsirolimus in refractory mantle-cell lymphoma demonstrated a 22% 
objective response rate (ORR) with temsirolimus compared with 2% for the 
investigator’s choice of therapy139. This translated into a statistically significant three 
month improvement in PFS. A phase II study in non-Hodgkin’s lymphoma produced 
similar response rates of 35%
135
. Other phase II trials in patients with sarcoma and 
endometrial cancer have also shown promise. There is also interest in the use of 
rapalogs in the treatment of syndromes of proliferative dysregulation such as tuberous 
sclerosis and neurofibromatosis. 
 
In most of the larger trials to date the objective response rates have been modest. In 
the phase III study of temsirolimus in poor prognosis renal cell carcinoma there was 
an ORR of only 8.6% despite significant improvement in PFS and OS
137
, and in the 
everolimus study the ORR was even less at 1%
138
. This may not be surprising given 
the known cytostatic effect of rapamycin and its effect on tumour vasculature. Thus, 
for mTOR inhibitors, high ORR may not be required to achieve good clinical benefit.  
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3.1.4 Combination Therapy with mTOR inhibitors 
 
Given the cytostatic nature of mTOR inhibitors, and the consequent disease 
stabilisation rather than regression seen with their single-agent use in clinical trials, it 
is likely that most of these drugs will used in combination therapy. Many of the 
molecularly targeted agents entering clinical trials are paired with conventional 
cytotoxic drugs based on standard of care guidelines rather than a strong scientific 
rationale. However, as our understanding of mTOR and its inhibition increases, it 
raises the possibility of pairing mTOR inhibitors with other signalling pathway 
inhibitors, and targeted agents, to optimise antitumour effects
121
.  
 
mTOR inhibitors have been shown to be additive or synergistic in combination with a 
number of conventional chemotherapy agents. Rapamycin potentiates the cytotoxicity 
of paclitaxel, carboplatin and vinorelbine and enhances apoptosis in breast cancer cell 
lines
115
. Synergy was found to be sequence dependent with significant increases in 
apoptosis seen only when rapamycin was given after paclitaxel. Similarly, everolimus 
enhances cisplatin sensitivity in hepatocellular carcinoma
140
 again with evidence of 
increased apoptosis when used in combination. Everolimus inhibits ovarian cancer 
cell proliferation in Akt driven cell lines and enhances cisplatin-induced apoptosis
141
. 
When this combination was tested in vivo it significantly prolonged survival. A phase 
I study in patients with advanced solid tumours demonstrated that the combination 
everolimus and paclitaxel was safe at the doses given, and 11 out of the 16 patients 
entered reported disease stabilisation for at least 3 months
142
.  
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Rapamycin and everolimus are also potent radiosensitisers partly through mTOR-
dependent enhancement of radiation induced autophagy
143,144
. Prostate cancer cell 
lines, PC-3 and DU145, are more susceptible to radiotherapy after treatment with 
everolimus in vitro
145
. This was more pronounced in the PTEN-deficient PC-3 cell 
line and this increased sensitivity is associated with the induction of apoptosis. In vivo 
models of pancreatic and colon cancer also indicate additive tumour growth delay 
when using everolimus in combination with radiation
146
. Also, radiation activates 
mTOR signalling in the vascular endothelium and mTOR inhibitors increase 
apoptosis of endothelial cells in response to radiation
146,147
. 
 
Akt/mTOR signalling has been associated with resistance to endocrine therapy in 
breast cancer
148
 and there has been interest in combining endocrine therapy with 
mTOR inhibitors. Preclinical models have suggested an increase in efficacy when 
rapalogs are combined with a range of hormone treatments including tamoxifen, 
letrozole, and fulvastrant
149,150
. However, a phase III randomised control trial of 
letrozole with or without temsirolimus showed no benefit in PFS at interim analysis. 
The combination of letrozole and everolimus appears more promising with a large 
phase II neoadjuvant study, in oestrogen receptor positive patients, indicating 
improved response rates
151
. However, toxicity was significant in the combination 
group, which may limit the use of everolimus in this setting. A large phase three 
randomised control trial comparing exemestane with exemestane and everolimus in 
patients with oestrogen receptor positive breast cancer has recently been published. It 
demonstrated a significant improvement in progression free survival in patients 
treated in the combination arm and its use is now licensed in combination with 
exemestane in patients with metastatic breast cancer that has progressed on an 
aromatase inhibitor
152
.  
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3.1.5 mTOR inhibitors and Oncolytic viruses 
 
A number of different oncolytic viruses have now been tested in combination with 
mTOR inhibitors including: adenovirus, myxoma, vaccinia virus and herpes simplex 
virus. Rapamycin has been shown to synergistically sensitise glioblastoma cells to the 
adenovirus OBP-405
153
. The synergy observed was thought to be due to stimulation 
of the autophagic pathway. In a mouse glioblastoma model, the same group showed 
that there was a significant increase in survival if everolimus was administered with 
OBP-405 compared with everolimus alone. In a similar glioma model, the adenovirus 
Delta-24-RGD was combined with everolimus and led to a significant improvement 
in survival
154
. Immunostaining of the tumours showed upregulation of Atg5, 
indicating the therapeutic induction of autophagy. Finally, an adenovirus, with an 
integrin-targeting peptide insertion to enhance tumour infection, combined with 
everolimus in a mouse colorectal model substantially prolonged the survival of the 
mice
43
. The authors suggested that the antiangiogenic properties of everolimus cause 
collapse of the tumour vasculature trapping virus and facilitating local spread within 
the tumour.  
 
Myxoma virus permissiveness in tumour cells appears to be intimately tied to the 
activation state of Akt kinase. M-T5, a host range factor of myxoma virus, interacts 
directly with Akt and mediates myxoma virus tumour cell tropism. By pre-treating 
with rapamycin, non-permissive cells show marked viral tropism and spread in vitro, 
and this is concomitant with an increase in Akt
62
.  Myxoma virus has been combined 
with rapamycin in two different preclinical models. Medulloblastoma cells are 
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susceptible to myxoma virus in vitro, and the extent of oncolysis is increased if the 
cells are pretreated with rapamycin. Oncolysis with intratumoural injection of 
myxoma virus in a mouse medulloblastoma model was also enhanced by rapamycin 
and there was a significant increase in survival in the combination group
63
. Similar 
synergy was seen in an immunocompetent mouse melanoma model. Combination 
therapy of myxoma virus with rapamycin reduced both size and number of lung 
metastases
64
. There was also a reduction in the induced antiviral antibody titres.  
 
Vaccinia virus has been combined with rapamycin both in vitro and in vivo. 
Combination therapy with vaccinia virus and rapamycin promoted oncolysis in rat 
glioma cell lines
155
. Pre-treatment with rapamycin resulted in greater cell killing and 
viral gene expression. Measurement of viral titres showed that rapamycin 
significantly enhanced viral replication in glioma cell lines compared with media 
alone. In vivo, the combination of intravenously delivered vaccinia virus and 
rapamycin enhanced viral replication and prolonged survival. Viral titres from tumour 
tissues showed that more viral replication occurred in tumours treated with 
combination therapy.  
 
The combination of the oncolytic herpes simplex virus, Baco-1, and rapamycin had no 
effect on cells that were sensitive to Baco-1. However, in cells that were resistant or 
semi-permissive the yield and dissemination of HSV was significantly increased. This 
result was confirmed in a mouse model, with no effect on tumour growth with either 
agent alone, but significant regression seen with the combination
156
. The mechanism 
by which rapamycin potentiates HSV oncolysis has not yet been elucidated.  
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There are no published studies assessing the combination of reovirus and mTOR 
inhibitors. The aberrant Ras pathway utilised by reovirus lies upstream of mTOR and 
the effect of mTOR inhibition on reovirus oncolysis is uncertain. 
 
3.2 Study Objectives  
The objectives of this study were to assess the novel combination of reovirus with 
mTOR inhibitors. Rapamycin was chosen as it is the archetypal mTOR inhibitor and 
for its ease of use. The aims were: 
 To assess the effect of rapamycin on reovirus oncolysis in vitro. 
 To determine the effect of rapamycin on reovirus replication.  
 To examine the mechanism of cell death with the combination of reovirus and 
rapamycin. 
 To describe changes in signal transduction associated with the combination of 
reovirus and rapamycin. 
 To assess the combination of reovirus and rapamycin in an in vivo mouse 
melanoma model. 
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3.3 Results 
3.3.1 Concomitant Reovirus and Rapamycin is antagonistic in B16.F10 Cells 
To determine the effect of concomitant reovirus and rapamycin in the mouse 
melanoma cell line, B16.F10, cell viability was assessed after 48 hours of exposure to 
each agent, using the MTS assay as described in chapter 2. B16.F10 was found to be 
permissive to reovirus with a medium effective dose (ED50) between 1 and 5 MOI 
(Figure 3.2). Rapamycin also decreased cell viability with an ED50 between 1nM and 
5nM (Figure 3.2).  
 
Having established the ED50, rapamycin and reovirus were then combined at 0.25, 
0.5, 1, 2, 4 times the ED50 of each agent using a constant ratio chequerboard design 
as described in chapter 2 (Figure 3.2). The effect of rapamycin and reovirus on cell 
viability was reproducible with less than 0.01% chance of randomly observing an 
effect this large with an experiment of this size (2-way ANOVA; p<0.0001). 
However, Bonferroni post-tests showed no significant difference between the means 
at each dose level for single agent and combination treatment. The effect of the 
combination of reovirus and rapamycin on cell viability was assessed by isobologram 
analysis and the calculation of combination indices (CI). The CI provides a 
quantitative measure of the degree of interaction between two agents. A CI of 1 
denotes an additive interaction, >1 antagonism and <1 synergy. With the concomitant 
administration of reovirus and rapamycin there was evidence of antagonism with a 
combination index at ED50, ED75, and ED90, of 1.6, 1.7 and 2.6 respectively (Figure 
3.2).
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Figure 3.2: Combination of concomitant rapamycin and reovirus in B16.F10 
cells is antagonistic  A and B, Reovirus and rapamycin induce cell death in a dose 
dependent manner. Cells were exposed to reovirus or rapamycin and an MTS assay 
was performed after 48 hours exposure. C, Administration of concomitant rapamycin 
does not enhance reovirus induced cell kill. Cells were exposed to 0.25, 0.5, 1, 2, 4 x 
calculated ED50 for each agent and cell survival estimated using MTS assay after 48 
hours. D, Classic isobologram indicates that the concomitant use of reovirus and 
rapamycin is antagonistic (observed ED50, ED75, ED90 lie to the right of their 
respective hypothenuse) 
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3.3.2 Cytotoxicity is affected by the sequence of combination treatment  
Given that synergy with rapamycin is sequence dependent with certain 
chemotherapeutic agents
115
, we wanted to evaluate the effect of the sequence of 
reovirus and rapamycin on cell viability. Cells were plated on 96-well plates and 
exposed to single agent rapamycin, reovirus or a combination as described earlier. 
However, two further groups were added: reovirus followed 24 hours later by 
rapamycin, and rapamycin followed 24 hours later by reovirus. Twenty-four hours 
was chosen as a previous study demonstrated optimal cell kill when an mTOR 
inhibitor was given 24 hours after paclitaxel
115
. All cells were assessed for viability by 
MTS assay, 48 hours after the first treatment was given.  
 
Again the experiments were reproducible with a significant difference between the 
treatments using 2-way ANOVA (p<0.0001). Bonferroni post-tests were performed 
on each experiment. When rapamycin was given before reovirus there was no 
difference between the means at each dose level between that combination and 
rapamycin alone. However, when rapamycin was given after reovirus there was a 
significant difference between the means at each dose level compared with either 
agent alone (p<0.001). Also, the combination of rapamycin and reovirus was found to 
be synergistic by isobolographic analysis only when reovirus was followed by 
rapamycin, with a CI value of 0.5, 0.4, and 0.4 for the ED50, ED75 and ED90 
respectively. When rapamycin was given before reovirus there was similar evidence 
of antagonism as seen with concomitant treatment with a CI value of 1.3, 1.9, and 2.7 
for the ED50, ED75 and ED90 respectively (Figures 3.3 and 3.4; Table 3.1) 
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Figure 3.3 Rapamycin enhances reovirus cytotoxicity in a sequence dependent 
manner  Cells were exposed to rapamycin and reovirus at 0.25, 0.5, 1, 2, 4 x 
calculated ED50 for given exposure time and combined as follows: A, rapamycin 
followed 24 hours later by reovirus. B, concomitant rapamycin and reovirus. C, 
reovirus followed 24 hours later by rapamycin. 48 hours after exposure to first drug, 
cell viability was assessed using the MTS assay. Survival was calculated as a 
percentage compared to untreated cells for each separate experiment. 
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 ED50 ED75 ED90 
Rapamycin→ 
Reovirus 
1.29±0.10 1.86±0.08 2.65±0.3 
Rapamycin/ 
Reovirus 
1.61±0.12 1.74±0.20 2.58±0.77 
Reovirus→ 
Rapamycin 
0.51±0.02 0.46±0.07 0.48±0.1 
 
 
Figure 3.4 Sequence of reovirus then rapamycin is synergistic 
The classic isobologram for the sequenced combination of reovirus followed by 
rapamycin shows synergy at all effective dose levels (observed ED50, ED75, ED90 
lie to the left of their respective hypothenuse).  
Combination Indices were generated using Calcusyn software. Data is presented as 
combination index value ± standard error of the mean at the effective dose indicated. 
Synergy was only seen when rapamycin was given 24 hours after reovirus.  
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3.3.3 Concomitant reovirus and rapamycin reduces viral production 
To assess the effect of rapamycin on viral replication, plaque assays were performed 
as described in chapter 2. Flasks seeded with B16.F10 cells were exposed to reovirus 
alone, concomitant reovirus and rapamycin, rapamycin followed 24 hours later by 
reovirus, and reovirus followed 24 hours later by rapamycin. After 48 or 72 hours the 
flasks were transferred to a -80°C freezer and the resulting supernatant serially diluted 
and allowed to infect L929 cells before an overlay was added. 
 
The length of time cells were exposed to treatment led to a significant difference in 
the number of viral plaques in all treatment groups (2-way ANOVA; p< 0.0001). Both 
pre-treatment with rapamycin, or concomitant reovirus and rapamycin, significantly 
reduced the number of plaques (Bonferroni post-test; p<0.001) (Figure 3.5). However, 
when reovirus preceded rapamycin there was no significant difference in plaque 
number compared to reovirus alone (Bonferroni post-test; p<0.001). These results 
indicate that rapamycin knocks down viral replication when given together or prior to 
reovirus but that this effect is lost if rapamycin is given after the virus. Significantly 
more plaques were seen at 72 hours than 48 hours, but the difference between the 
treatment groups remained the same indicating that the effect of rapamycin on 
reovirus persists over this additional time period. 
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Figure 3.5 Rapamycin reduces viral replication 
Plaque assays were performed in 6 well plates using a L929 cell monolayer. B16.F10 
cells were infected with reovirus with or without rapamycin, concomitantly or in 
sequence. Serial dilutions, 10
-4
 to 10
-9
, of resulting supernatant at 48 or 72 hours were 
prepared. A, illustrates the difference in plaques with reovirus alone and concomitant 
treatment. B, rapamycin reduces reovirus replication when given before or 
concomitantly with reovirus. Rapamycin given after reovirus does not effect reovirus 
replication. 
Reovirus  
Reovirus + 
Rapamycin 
 93 
3.3.4 Apoptosis is reduced with concomitant administration of reovirus and 
rapamycin 
To assess the contribution of apoptosis to the mechanism of cell death with the 
combination of reovirus and rapamycin, two apoptosis assays were used. In apoptotic 
cells, the membrane phospholipid phosphatidylserine (PS) is translocated from the 
inner to the outer leaflet of the plasma membrane, thereby exposing PS to the external 
cellular environment. Annexin V is a Ca2+ dependent phospholipid-binding protein 
that has a high affinity for PS, and binds to cells with exposed PS. Viable cells with 
intact membranes exclude PI, whereas the membranes of dead and damaged cells are 
permeable to PI. Cells were exposed to reovirus and rapamycin as single agents or in 
combination and 72 hours later the percentage of early and late apoptotic cells 
estimated.  
 
Using the Annexin V / PI assay, the difference in the percentage of early apoptotic 
cells between treatments was significant (1-way ANOVA; p<0.001). Bonferroni’s 
multiple comparison test showed there was a significant reduction in the percentage of 
early apoptotic cells when rapamycin was given prior to, or concomitantly with, 
reovirus (p<0.05). However, when rapamycin was sequenced after reovirus there was 
no significant difference compared with reovirus alone(Figure 3.6 and 3.7).  
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Figure 3.6 FACS Analysis of Annexin V / PI staining 
Cells were exposed to reovirus and rapamycin, alone or in combination, and the level 
of Annexin V / PI staining estimated using FACS analysis. Cells in the lower right 
quadrant (A
+
;PI
-
) are in early apoptosis, cells in upper right quadrant (A
+
;PI
+
) are in  
late apoptosis. Rapamycin reduced reovirus-induced apoptosis unless given after 
reovirus. 
Control Reovirus 
Rapamycin Concom 
Reovirus→ 
Rapamycin 
Rapamycin 
→Reovirus 
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Figure 3.7 Reovirus-induced apoptosis is reduced by pre- or concomitant 
treatment with rapamycin, as determined by Annexin/PI staining by FACS analysis 
(top), and Caspase 3 activation  using CaspaseGlo Assay (bottom) 
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Caspase-3/7 is a recognised marker of apoptotic induction inside cells. The presence 
of activated caspase-3/7 suggests a cell that is proceeding towards a terminal pathway 
of cell death. Caspase-3 is an‘executioner’ caspase whose activation leads to the 
cleavage of a wide range of proteins including PARP and ICAD in the downstream 
events during apoptosis.  
 
Treatment with reovirus alone led to a significant increase in caspase 3/7 activation 
compared with untreated cells (1-way ANOVA). As seen with the Annexin V / PI 
assay, when rapamycin was used as a single agent, or before or concomitantly with 
reovirus there was a reduction in the activation of caspase 3/7 (p<0.001). However, 
when reovirus infection preceded rapamycin treatment there was no significant 
difference in caspase 3/7 activation compared to reovirus treatment alone (Figure 3.7).  
 
3.3.5 Rapamycin does not increase autophagy in B16.F10 cells 
To investigate an alternative mechanism for cell death in reovirus and rapamycin 
treated B16.F10 cells, we assessed the induction of autophagy in these cells.  It has 
been shown that some rotaviruses induce the formation of autophagosomes as a site 
for replication
157
. As well as inducing apoptosis, reovirus has been shown to 
upregulate autophagy during oncolysis of multiple myeloma
158
. Also reovirus induces 
autophagy in some head and neck cell lines (K.Harrington, personal communication). 
Autophagy is a form of programmed cell death that is distinct from apoptosis. It is a 
type of protein degradation system whereby cytoplasmic proteins are sequestrated into 
lytic components and is characterised by the formation of acidic vesicular organelles 
(AVO). To detect these organelles vital staining with acridine orange was used as 
described in chapter 2.6. In acridine orange-stained cells, the cytoplasm and nucleolus 
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fluoresce bright green and dim red, whereas acidic compartments fluoresce bright 
red
159
. The intensity of the red fluorescence is proportional to the cellular acidic 
compartment and by measuring the red:green fluoresce ratio in different cell 
populations the degree of autophagy can be estimated
160
. Significance was 
demonstrated by 1-way ANOVA and Bonferroni multiple comparison tests. 
 
Cells starved with 2%FCS for 48 hours showed a slight increase in AVO formation 
compared with 10%FCS controls (Figure 3.8 and 3.9). In cells treated with 10 MOI of 
reovirus, there was a significant increase in AVO formation compared to 2%FCS 
controls from 15% to 30% (p<0.05), implying an in increase in autophagy in reovirus 
infected cells. There was no difference in AVO formation in cells treated with 10μM 
rapamycin compared with 2%FCS controls. However, when rapamycin was given at 
the lower dose of 10nM there was a significant reduction in the formation of AVOs 
(p<0.05). When rapamycin was given with reovirus there was a reduction in AVO 
formation compared with reovirus alone. This difference is most striking if the 
rapamycin is given prior to or concomitantly with reovirus, whereas rapamycin given 
after reovirus shows no difference compared to FCS2% control. Thus rapamycin 
appears to decrease autophagy in B16.F10 cells whereas reovirus causes a marginal 
increase in autophagy, with this effect being reduced by the addition of rapamycin.  
 98 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Acridine Orange Autophagy Assay 
The degree of red/green fluorescence after staining with acridine orange was 
estimated using FACS analysis. Cells in the upper left and right quadrants show a red 
shift and are considered to be undergoing autophagy.
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Figure 3.9 Percentage of Autophagic Cells by FACS analysis 
Reovirus alone caused a modest increase in autophagic cells compared to 2%FCS 
control. Rapamycin significantly reduced the degree of autophagy compared to 
reovirus alone. This was seen whether rapamycin was given before, with, or after 
reovirus. 
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3.3.6 The effect of reovirus, rapamycin or combination on the cell cycle 
B16.F10 cells were exposed to reovirus and rapamycin, concomitantly or in sequence.  
For comparison, NIH3T3 (mouse embryonic fibroblast) cells were exposed in the 
same permutations. In NIH3T3 cells, rapamycin exposure led to increased G0/G1 
fraction and marked lowering of G2/M and S phase fractions which was unaffected by 
the later addition of reovirus. Reovirus exposure also resulted in reduction in G2/M 
and S phase, but to a lesser extent than with rapamycin, and this reduction was largely 
unaffected by concomitant or sequential exposure to rapamycin.  In the cancer cell 
line B16.F10, the effects of all treatment permutations resulted in more marked 
increases in G0/G1 fraction, and more marked reduction in G2/M and S phase 
fractions. Again the highest reduction in G2/M and S phase fractions were in 
association with rapamycin, but similar to NIH3T3 cells the effects of reovirus were 
not altered by rapamycin in the combination groups (figure 3.10). 
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Figure 3.10 The effect of reovirus and/or rapamycin on cell cycle.  
Rapamycin exposure results in most marked reduction of G2/M and S phase fractions. 
In both NIH3T3 cells and B16F10 cells, prior or concomitant exposure to reovirus 
reduces this effect. 
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3.3.7 Combined reovirus and rapamycin treatment enhances tumour growth 
delay and prolongs survival in a mouse melanoma model 
 
The in vivo effects of reovirus, rapamycin and their combination were assessed in a 
mouse melanoma model using B16.F10 cells in C57/BL6 mice. Cells were implanted 
subcutaneously in the flank of the mice and treated when they had reached an average 
diameter of 4.5-5.5mm, usually 10 days after implantation. Mice were then treated 
with intratumoural reovirus, intraperitoneal rapamycin, or both, as described in the 
methods. There were no obvious toxic effects of either single agent or combination 
treatments and experiments were concluded if tumour growth exceeded 15mm in any 
one dimension or there was ulceration of the tumour.  
 
Both rapamycin and reovirus alone resulted in a significant reduction in tumour 
growth compared to control (2-way ANOVA p<0.0001), however the combination of 
the two, whether concomitant or in sequence, resulted in the most effective growth 
delay (Figure 3.12). The median survival for the control, rapamycin, reovirus, 
sequence, and concomitant groups was 8, 11, 14, 15, and 17 days respectively (Figure 
3.13). There was no significant difference in median survival between concomitant 
and sequenced treatment, and the difference between sequenced treatment and 
reovirus alone did not reach significance either. However, the difference in survival 
between the concomitant group and reovirus alone did reach significance (Log-rank 
test; p=0.02). 
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Figure 3.11 Reduced tumour growth following reovirus/rapamycin treatment 
C57Bl/6 mice with a B16.F10 flank tumour were treated with i.t. reovirus (days 1 and 
4), i.p. rapamycin (days 1,4,8,and 11), or a combination (concomitant or with 
rapamycin 24hrs after reovirus). Growth was measured as tumour diameter, A, or 
tumour volume, B, expressed as tumour volume relative to volume at commencement 
of treatment. Concomitant treatment led to significantly slower tumour growth 
compared to either agent alone. 
A 
B 
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Figure 3.12 Improved survival following reovirus/rapamycin treatment 
Concomitant treatment with reovirus and rapamycin led to a significant improvement 
in median survival compared to reovirus or rapamycin alone (log-rank test; p0.02). 
There was no significant difference between combination treatment given in sequence 
or concomitantly.  
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3.3.8 Viral replication in tumour and organs of treated mice 
 
To assess the effect of rapamycin on reoviral replication in vivo, we evaluated viral 
replication in tumours and organs 4 days after treatment with either reovirus alone, 
concomitant reovirus and rapamycin, or reovirus followed 24 hours later by 
rapamycin. Following sacrifice of the animals on day 4, viral titres were determined 
using plaque assays as described in chapter 2. As expected, the highest viral yield was 
in the resected tumour, with the liver having the highest yield of the organs collected 
(Figure 3.14). There was no difference in virus titre in the lung, liver or heart between 
the treatment groups. There was, however, a difference in the viral titre in the resected 
tumours with a significant increase in virus seen in the sequence group compared to 
the reovirus alone group (unpaired t-test; p=0.03). There was no significant difference 
between the sequence or concomitant groups and neither was there a difference 
between the concomitant and reovirus alone groups. 
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Figure 3.13 Viral replication in tumour and organs 
B16.F10 tumours were seeded on the flanks of C57Bl/6 mice. Mice were treated with 
reovirus i.t. either alone or in combination with i.p rapamycin on days 1 or 2, viral 
titre in tumour (a), liver (b), lungs (c) and heart (d) was determined using plaque 
assay. Data shown is representative of mean plaque forming units per gram of tissue. 
There was a significant difference (*) in pfu/g of tissue in the tumour group between 
mice treated with reovirus alone and the sequenced combination (unpaired t-test; 
p=0.03). 
* 
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3.3.9 Rapamycin does not alter the production of neutralising anti-reoviral 
antibodies  
Rapamycin is known to have immunosuppressive properties. The combination of 
other immunosuppressive agents with reovirus has been shown to reduce the humoral 
response and improve the antitumour effects of reovirus
39
. Similarly, other oncolytic 
viruses have shown improved efficacy with immunosuppressive agents
64,155
. To 
determine whether the synergy demonstrated in vivo between reovirus and rapamycin 
could be due to attenuation of the humoral response by rapamycin, we assessed the 
NARA response to reovirus and the reovirus/rapamycin combination, both 
concomitant and sequential, in C57BL/6 mice. Using a previously reported assay
113
, 
we found that, at the dose of 5mg/kg, rapamycin had no significant effect on the 
NARA response whether given concomitantly or sequentially (Figure 3.15). 
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Fig 3.14 Rapamycin does not affect the humoral response to reovirus at the 
dose of 5mg/kg. The level of neutralising antibody in the serum of tumour 
bearing mice treated with either reovirus alone, or in concomitant or sequenced 
combination was determined. Data is expressed as fold increase in neutralising 
antibody (Nab) titre. Data courtesy of Victoria Roulstone 
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3.3 Discussion 
Reovirus is a wild-type oncolytic virus that has activity in a broad range of cancers. It 
has been shown to be safe and tolerable when given both by intratumoural and 
intravenous injection
107,161
. While responses have been seen in patients with advanced 
malignancies the focus is now on combining reovirus with other treatments to try and 
improve efficacy
162
. A number of phase I trials have now been completed looking at 
the combination of reovirus with chemotherapy and also with radiotherapy. Another 
phase I trial assessing reovirus given with an immunomodulatory dose of 
cyclophosphamide is currently still recruiting. Pre-clinical studies showing synergy 
with these combinations have informed the design of these phase I studies
95
. 
 
In this work we assessed the combination of reovirus with the mTOR inhibitor 
rapamycin using a mouse melanoma model. Malignant melanoma is increasing in 
incidence and has a poor prognosis, except in early-stage disease, with few effective 
therapeutic options. There is therefore an urgent need for novel treatment strategies. 
The B16.F10 mouse melanoma model is well established, and the cells are hardy, 
easily manipulated in vitro and grow rapidly. It also allows in vivo experiments to be 
performed in an immunocompetent model. 
 
The mTOR inhibitors have been shown to have anticancer activity and are now in use 
in the clinical setting in patients with advanced renal cell carcinoma and metastatic, 
oestrogen receptor positive, breast cancer. The Akt-mTOR pathway is upregulated in 
up to 70% of malignant melanomas
163
 making mTOR inhibitors potential agents in 
these cancers. While there is some preclinical evidence of efficacy in melanoma 
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models
164
, a phase II trial of single agent rapamycin in metastatic malignant 
melanoma was disappointing with only one objective response in 34 patients
165
. 
However, the combination of mTOR inhibitors with both conventional and novel 
therapies has been shown to improve response rates in pre-clinical
141,166,167
 and 
clinical studies
168
.   
 
Data on the combination of mTOR inhibitors with four different oncolytic viruses has 
been published to date
43,63,64,156
. All three viruses displayed evidence of synergy in 
combination with mTOR inhibitors, with different hypotheses given for how the 
agents interact to increase cancer cell death. The potential mechanisms by which 
mTOR inhibitors might enhance viral oncolysis include: targeting of alternative 
signalling pathways, suppression of the antiviral immune response, and alteration in 
tumour vasculature through their antiangiogenic properties.  
 
In this study we assessed the novel combination of reovirus and rapamycin and also 
found evidence of synergy. However, at least in vitro, this synergy appears to be 
sequence dependent with the combination being antagonistic unless reovirus is given 
prior to rapamycin. Rapamycin is known to act as a cytostatic agent, being a potent 
inducer of G1 cell cycle arrest. We demonstrated that in cells exposed to rapamycin 
alone or before reovirus there was an increase in the proportion of cells in G0/G1 and 
a reduction in cells in G2/M. This may explain the antagonism seen in cells exposed 
to rapamycin before or concomitantly with reovirus, as work carried out by 
Heinemann et al. have shown that reovirus oncolysis is cell cycle dependent, 
occurring in S phase
96
. However, we have also shown that pre- or concomitant 
treatment with rapamycin reduces reovirus replication, as determined by viral plaque 
assay, which could account for the antagonism seen with these combinations. It would 
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also explain the reduction in apoptosis seen after pre- and concomitant treatment with 
rapamycin. 
 
Rapamycin is known to increase myxoma virus replication in certain cancer cell 
lines
62
 in vitro. However, this is thought to be due to rapamycin induced Akt 
activation, and the increased tropism of myxoma virus to cells with hyperactivation of 
Akt. Reovirus tropism is intimately related to the Ras pathway and there is now 
evidence that inhibition of mTORC1 leads to Ras/MAPK pathway activation
169
. 
Increasing activated S6K1 levels lead to PI3K inhibition via a negative feedback loop 
leading to a reduction in Ras/MAPK signalling. A similar feedback loop can lead to 
Akt activation in certain cell lines
133
. Other studies assessing rapamycin combined 
with myxoma virus and vaccinia virus in vivo have also demonstrated increased viral 
replication, although in both cases neutralising antiviral antibody production was 
suppressed and this was assumed to be the cause for increased viral yield from 
tumours.  
 
Though a cytostatic agent, rapamycin has also been shown to induce apoptosis in cells 
lacking functional p53
170,171
. In our model, rapamycin reduced apoptosis in B16.F10 
cells compared to untreated controls, whereas reovirus induced apoptosis, as has been 
demonstrated previously
95
. Reovirus also induces autophagy in B16.F10 cells, but 
unexpectedly rapamycin, which is known to induce autophagy in other cell lines, did 
not, even at micromolar doses. There are no published studies assessing autophagy in 
B16 melanoma cells exposed to rapamycin, however this may be a cell specific 
phenomenon as a study showing a reduction in lung metastases with rapamycin in a 
B16 mouse melanoma model found no evidence of autophagy
164
.  
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While the attenuation in reoviral replication and subsequent reduction in apoptosis 
and autophagy can explain the antagonism seen with pre- and concomitant treatment 
of cells with rapamycin, no increase in either apoptosis or autophagy was seen when 
reovirus was given prior to rapamycin, despite there being evidence of decreased cell 
survival by MTS assay. 
 
In the in vivo experiments, both single agent alone, and combination of rapamycin and 
reovirus resulted in a significant reduction in tumour growth and median survival. 
Combination treatment was significantly more effective than either treatment alone, 
however, unlike in the in vitro setting, there was no significant difference between 
concomitant and sequenced treatment. This may simply reflect the difference in 
treatment delivery, with the reovirus given intratumourally and the rapamycin via the 
peritoneum. One possibility for the synergy seen in other oncolytic virus models may 
be due to a reduction in the NARA response caused by rapamycin. However, we 
found no significant attenuation in the NARA response, which may reflect differences 
in the dose scheduling of rapamycin or the timing of NARA assessment after viral 
administration. It is also possible that attenuation of the immune response may reduce 
the efficacy of reovirus-induced immune priming
99
. Rapamycin reduces the interferon 
responses to viral infection
172
, but also suppresses T-cell function
173
. This suppression 
not only affects T-regulatory cells, which maybe undesirable, but also T-cell mediated 
viral responses which may actually improve reovirus infection. 
 
Another possible mechanism of synergy is the effect of rapamycin on the tumour 
blood supply. Alteration of the tumour vasculature due to antiangiogenic therapy such 
as rapamycin can lead to a ‘normalisation window’ whereby disorganised blood 
vessels transiently reorganise
42
, reducing hydrostatic barriers to virus delivery. The 
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subsequent withdrawal of rapamycin could then trap the virus within the tumour, as 
has been hypothesised in a colorectal mouse model combining adenovirus with the 
mTOR inhibitor, everolimus
43
. While this model confirmed ablation of the primary 
antibody response with everolimus in immunocompetent mice, synergy was also seen 
in an immunosuppressed xenograft model. The authors argued that the withdrawal of 
regular mTOR inhibitor causes vascular disruption trapping the virus and facilitating 
viral spread within the tumor. 
 
In this study we have demonstrated that the combination of reovirus with the mTOR 
inhibitor, rapamycin, is synergistic in a mouse melanoma model. While this appears 
to be sequence dependent in vitro, concomitant administration significantly improves 
survival in vivo. The mechanism for this synergy is uncertain though attenuation of 
the humoral response was not demonstrated. The combination of reovirus with other 
anticancer agents is currently being investigated in phase I and II trials. The 
combination of mTOR inhibitors with reovirus shows promise and further 
investigation is justified. 
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4.1 Introduction 
4.1.1 Epidermal growth factor receptor and its signalling pathway 
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is 
frequently expressed in epithelial tumours
174
. It belongs to a family of receptor 
tyrosine kinases that include three other members: erbB2/HER-2, erbB3/HER-3, and 
erbB4/HER-4. They all have a similar structure composed of an extracellular ligand-
binding domain, a short hydrophobic transmembrane region, and a cytoplasmic 
tyrosine kinase domain
175
. There are six known ligands that bind to EGFR, including 
epidermal growth factor (EGF) and transforming growth factor-α (TGF-α). Binding of 
ligands causes a conformational change of the receptor ectodomain and allows 
dimerisation and consequent phosphorylation of several tyrosine residues within the 
COOH-terminal tail of the receptors. Activation of EGFR can be ligand-dependent or 
independent, as well as due to overexpression of the receptor
176
. Ligand-independent 
receptor activation can occur through a number of mechanisms including cellular 
stresses, such as radiation, which switch off phosphatases that block the receptor 
kinase activity and thereby lead to increased phosphorylation of the receptor
177
. 
 
The phosphorylation of key tyrosine residues within the COOH-terminal portion of 
EGFR provides docking sites for cytoplasmic proteins that initiate intracellular 
signalling via several different pathways (Figure 4.1). These include: the 
Ras/Raf/mitogen-activated protein kinase (MAPK) pathway, the PI3K/Akt pathway, 
phospholipase Cγ, signal transducers and activators of transcription (STAT) pathway, 
and the Src kinase pathway. 
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Figure 4.1 EGFR signalling pathway 
Activation of EGFR leads to its homo/heterodimerization, phosphorylation of tyrosine 
residues (red circles), and recruitment of several proteins at the intracellular tail of the 
receptor. PLCγ (green) and STATs (grey) can interact directly with these residues, 
whereas Ras (orange) and PI3K (pink) require adaptor molecules. As well as the 
pathways shown, the activated receptor itself can undergo endocytosis and nuclear 
translocation. The endpoint of all these pathways is nuclear activation of genes related 
to survival, proliferation, invasion and metastasis. 
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The stimulation of these signalling pathways leads to the activation of numerous 
nuclear transcription factors such as Myc, Jun, Fos, Elk, Egr1 and Stat. These 
transcription factors have a wide range of effects including proliferation, inhibition of 
apoptosis, alteration in cell differentiation and changes in cell adhesion and migration. 
EGFR is normally expressed in all epithelial and stromal cells, however high levels 
have been observed in many tumours of epithelial origin, including head and neck, 
non-small cell lung, prostate, breast, colorectal, and pancreatic cancers, as well as 
gliomas. The overexpression of EGFR in many tumours and the central role of the 
erbB network in the development of solid tumours have led to efforts to target EGFR 
as an anticancer therapeutic. Two approaches have now entered clinical practice: 
targeting of the extracellular receptor with EGFR-specific antibodies, and EGFR 
tyrosine kinase inhibitors which block intracellular components of the signalling 
pathway. 
 
4.1.2 Effect of treatment on EGFR expression 
While many cancers have abnormal expression of EGFR, it is now clear that 
treatment with anti-cancer therapy can affect the levels and activation of EGFR. In 
some colorectal cancer cell lines exposure to oxaliplatin results in a dose-dependent 
increase in EGFR phosphorylation, whereas in others there is a dose dependent 
decrease
178
. In both cases there was no effect on the expression of total EGFR. The 
difference between the cell lines appeared to be in their basal phospho-EGFR levels 
which were significantly higher in the cells that had enhancement of EGFR 
phosphorylation with oxaliplatin. When the same researchers combined oxaliplatin 
with gefitinib, an EGFR tyrosine kinase inhibitor, they found synergy only in the cell 
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lines that displayed enhancement of EGFR phosphorylation with chemotherapy. In 
the other cell lines the combination was antagonistic. 
 
 Similar results in neuroblastoma cell lines have indicated that cisplatin treatment 
increases the expression of EGFR in a dose-dependent manner and that combination 
treatment with EGFR-targeted cytotoxic reagents significantly improved anti-cancer 
effects
179
. Interestingly, when an EGFR inhibitor was combined with cisplatin in 
cisplatin-resistant neuroblastoma cells, there was still a significant decrease in cell 
viability compared to either agent alone.  
 
Increase in the phosphorylation of EGFR is also seen in MCF7 breast cancer cells, 
and A431 lung cancer cells, exposed to ionizing radiation
180
. The activation of the 
EGFR pathway was demonstrated to be due to autophosphorylation of the receptor. 
The authors proposed that this stimulus is in part responsible for the accelerated 
repopulation seen in some cancers with ionizing radiation treatment. These results 
suggest that EGFR expression is often increased in cancer cells as a stress response 
and that by targeting this increased activation therapeutic gains can be made with 
combination treatment. 
 
4.1.3 Viruses and EGFR 
A number of viruses are known to constitutively elevate EGFR signalling by 
expressing an active component or by interfering with signalling shut-off
175
. A 
product of human papilloma virus (HPV), E5, interferes with EGFR degradation 
through inhibition of an endosomal proton-ATPase and also increases the rate of 
receptor recycling back to the cell surface
181
. The hepatitis B virus upregulates 
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transcription of the ErbB1 promoter
182
, while Epstein-Barr virus encodes a protein 
LMP1 that induces the expression of EGFR
183
. Many non-transforming poxviruses 
encode EGF-like ligands whose expression at sites of infection significantly increase 
their pathogenicity
184
.  
 
While there is evidence that viruses increase expression of EGFR and that this may 
enhance their pathogenicity, there are no reports on the effect of reovirus on EGFR 
expression. However, EGFR expression is known to have an effect on reovirus 
infectivity. It has been shown that in two relatively reovirus-resistant cell lines, that 
do not express EGFR, transfection with a gene encoding EGFR significantly increases 
their permissiveness to reovirus infection
73
. This effect was not observed in cells 
expressing a mutated EGFR, that lacked tyrosine kinase activity, implying that a 
functional EGFR is necessary for reovirus infection in these cells. Reovirus is also 
known to bind directly with the N-terminal extracellular domain of EGFRs
185
. 
Furthermore, NIH-3T3 cells, which have low expression of EGFR, are resistant to 
reovirus infection, but when they are transformed with the v-erbB oncogene they 
become highly permissive
74
. This is despite the fact that the v-erbB oncogene has a 
truncated extracellular binding domain. The conclusion drawn is that the mechanism 
of enhancement of reovirus infection conferred by EGFR is through the use by 
reovirus of an already activated signal transduction pathway. The fact that tyrosine 
kinase inhibition with genistein reverses this enhancement supports this hypothesis. 
 
The activation of the Ras pathway, or upstream or downstream elements of the 
pathway, is known to be an important factor in a cell’s permissiveness to reovirus. 
Activated Ras prevents the phosphorylation of cellular PKR which in normal cells 
blocks viral synthesis. EGFR is an important upstream component of the Ras pathway 
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and consequently changes in EGFR expression may alter the oncolytic activity of 
reovirus.  
 
4.2 Study Aims 
Microarray analysis of B16.F10 cells infected with reovirus showed increased 
expression of the EGFR gene compared to untreated controls. We therefore planned 
to investigate this finding further by: 
 determining whether this increased gene expression was seen in other cancer cell 
lines 
 confirming that increased gene expression translated into increase in protein levels 
  evaluating the effect on cell viability of knocking down EGFR expression prior to 
infection with reovirus 
 
4.3 Methods 
Described in chapter 2 
 
4.4 Results 
4.4.1 EGFR gene expression is increased in B16.F10 cells infected with reovirus 
Microarray analysis of gene expression was performed on B16.F10 cells exposed to 
reovirus. Cells were plated in 6-well plates and exposed to reovirus MOI 25 for 24 
hours before RNA was extracted and the microarray protocol performed as described 
in Chapter 2. The results found a significant increase in the gene expression of 
EGFR1 (Figure 4.2). 
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Figure 4.2 Transcriptional changes in B16.F10 cells treated with reovirus by 
microarray analysis 
Changes in expression are shown as fold change relative to untreated cells. EGFR1 is 
highlighted in red. (Courtesy of L.Heinemann) 
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4.4.2 EGFR expression with reovirus infection varies with cell line 
 
To see whether upregulation of EGFR with reovirus infection was seen in other 
cancer cell lines, both mouse and human, the same experiment was repeated, exposing 
cells to their respective ED50 (at 48 hours) for 24 hours and extracting the RNA. 
Three separate experiments were performed for each cell line and the levels of EGFR 
quantified using qPCR. The ratio of EGFR expression was determined by comparing 
the mean EGFR expression in treated and untreated cells. Two mouse melanoma cell 
lines, B16.F10 and K1735 were assessed. The human cancer cell lines analysed were: 
prostate carcinoma, PC3 and DU145, breast carcinoma, MCF7, renal cell carcinoma, 
Caki-2, colon adenocarcinoma, HT-29, and malignant melanoma, Mel888. 
 
The ED50 for the cell lines used ranged from MOI3 for Mel888 to MOI600 for the 
resistant Caki-2 cell line. All the other cell lines ED50s lay between MOI10 and 
MOI20. There was no obvious correlation between the basal expression of EGFR, as 
measured by PCR, and the sensitivity of the cell to reovirus. In all cells, apart from 
Mel888, there was an increase in the level of EGFR expression with reovirus infection 
compared to untreated controls (Figure 4.3). In four cell lines, B16.F10, Caki-2, PC3 
and DU145, there was more than a threefold increase in EGFR expression. 
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Figure 4.3 Change in EGFR expression in cells exposed to reovirus 
The change in EGFR expression in cells exposed to reovirus for 24 hours at the ED50 
for the respective cell line, was determined using qPCR and expressed as a ratio 
compared to untreated controls. Results are representative of three repeat experiments. 
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4.4.3 Western Blot analysis of EGFR expression in reovirus infected cells 
 
To determine whether the increase in EGFR expression seen with PCR translates into 
an increase in protein levels, western blot analysis was performed. Cells were treated 
as for the PCR experiment, with cells exposed to reovirus at their ED50 for 24 hours 
prior to collection. Lysate preparation, protein concentration estimation, and western 
blot analysis was performed as described in Chapter 2.2. The experiment was repeated 
four times and western blots performed for each repeat. Results are representative of 
at least two repeats. The antibodies used targeted total EGFR (phosphorylated and 
unphosphorylated) as well as phosphorylation at the following tyrosine residues: 992, 
1068 and 1173. Not all the antibodies available were reactive with mouse species and 
therefore only human cell lines were assessed. The pEGFR Tyr 992 failed to work 
reliably and therefore this data is not shown. 
 
Despite the difference in EGFR expression as measured by PCR, there was no 
difference in total EGFR levels in the untreated and treated groups in all cell lines 
(Figure 4.4). This was consistent for all experimental repeats. However, there were 
changes seen in the levels of pEGFR in some cell lines. The cell line showing the 
most consistent and marked increase in pEGFR after infection with reovirus was the 
prostate carcinoma cell line DU145. This showed significant increases in levels of 
both pEGFR Tyr 1068 and Tyr 1173. Both PC3 and HT29 had increases in pEGFR 
Tyr 1173 in two of the four experimental repeats. There was no significant difference 
between treated and untreated cells in the Caki-2 cell line with either pEGFR antibody 
in any of the four experimental repeats. 
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Figure 4.4  Western Blot analysis of EGFR protein expression in reovirus 
infected cells 
To evaluate changes in EGFR protein levels in cells exposed to reovirus for 24 hours 
at their ED50, western blot analysis was performed. Lanes are paired by cell line 
showing untreated next to treated samples. Blots are representative of four 
experimental repeats. 
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4.4.4 Effect of EGFR knockdown on cell viability in reovirus-infected cells 
 
To assess the role of EGFR in reovirus induced cytotoxicity, the effect on cell 
viability of knocking down EGFR prior to reovirus infection was determined. 
Knockdown of EGFR was achieved using the Silencer siRNA starter Kit (Ambion) as 
described in Chapter 2.7 having first determined the optimal number of cells and 
concentration of transfection reagent. Cells were plated and transfected with EGFR 
siRNA in duplicate with one group being used to assess the degree of knockdown by 
qPCR and the other being used for cell viability experiments. 
 
Initial experiments with the PC3 cell line showed that EGFR knockdown was 
achieved with two of the three siRNAs used. However, the degree of knockdown was 
not optimal being between 30-40%. Viability of the cells transfected with siRNA after 
exposure to reovirus for 48 hours was assessed by MTS assay. There was no 
significant difference in cell survival between normal controls and cells with EGFR 
knockdown. See figure 4.5. 
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Figure 4.5 EGFR Knockdown with siRNA in PC3 Cells 
A, Degree of EGFR knockdown by 3 siRNAs, and a siRNA –ve control, was assessed 
using qPCR. Data are expressed as percentage EGFR expression relative to untreated 
controls. B, Cell viability, assessed by MTS assay, in cells exposed to reovirus. Cells 
were pretreated with medium alone, siRNA –ve control, or one of three EGFR 
siRNAs: s563, s564, and s565. 
 128 
 
4.5  Discussion 
EGFR is one of a family of receptors that on activation leads to intracellular signalling 
by a number of molecular pathways including Ras/Raf/MAPK, PI3K/Akt, and 
phsopholipase C. The end result of signalling via many of these pathways is the 
stimulation of genes related to cell proliferation and survival. Abnormal signalling via 
EGFR, whether due to overexpression or persistent activation, is seen in a large 
proportion of epithelial tumours. Cellular EGFR expression is known to increase after 
treatment with conventional cytotoxic agents acting to promote cell survival and 
attempts to block EGFR signalling in this setting has shown potential benefits. 
 
The permissiveness of some cell lines to reovirus infection has been shown to be 
enhanced by the addition of a verb-B oncogene. The increase in infectivity is thought 
to be related to the increased activation of Ras which blocks the phosphorylation of 
double-stranded RNA activated PKR allowing reovirus replication to proceed 
unchecked. Although reovirus binds to EGFR it is not thought this has any bearing on 
its ability to infect cells. 
 
In this study we further investigated the finding that EGFR1 gene expression was 
increased after exposure to reovirus. Microarray analysis of B16.F10 cells before and 
after exposure to reovirus showed a significant increase in the expression of EGFR1 
in cells treated with reovirus MOI25 for 24 hours. An MOI of 25 is a comparatively 
high dose of reovirus, translating to the ED90 for B16.F10 cells at 48 hours. It should 
be noted that microarray analysis provides a snapshot of gene expression at a given 
time point and that levels of gene expression may change significantly depending on 
the experimental conditions and timing of RNA extraction. Indeed, a repeat 
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microarray with B16.F10 cells at a lower MOI of reovirus failed to confirm the 
significant increase in EGFR expression. 
  
In this study we showed that there was a five-fold increase of EGFR expression in 
B16.F10 cells, at the lower dose of MOI10 (ED50 at 48 hours), as determined by 
qPCR. This increase was seen in other tumour cell lines both murine and human. Of 
the eight assessed, only the melanoma cell line Mel888 failed to display an increase in 
EGFR expression. This increase in EGFR was seen both in cells resistant (Caki-2) and 
permissive to reovirus (PC3).  
 
EGFR protein expression was assessed by western blot analysis and showed that 
although levels of total EGFR did not vary with exposure to reovirus, in certain cell 
lines there was an increase in the amount of phosphorylated EGFR. Though the HT-
29 and PC3 cell lines both showed increased expression in some western blots, 
particularly at tyrosine residue 1173, the cell line showing the most consistent 
upregulation of pEGFR was the prostate adenocarcinoma cell line DU145. Exposure 
to reovirus caused increased levels of pEGFR at tyrosine residue 1068 as well as 
1173. Phosphorylation of tyrosine residue 1068 allows binding of the adaptor protein 
Grb2
186
 and phosphorylation of tyrosine residue 1173 provides a docking site for the 
scaffold protein Shc
187
.  Both sites are involved in the activation of MAP kinase 
signalling and in particular the activation of Ras.  
 
The fact that there is increased activation of this pathway after reovirus infection is of 
interest given the critical role that activated Ras is thought to play in a cell’s 
permissiveness to reovirus. The finding suggests the possibility of an autocrine loop 
whereby reovirus infection itself increases viral protein synthesis by upregulating Ras 
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and blocking the activation of PKR. Alternatively, the increased expression of EGFR 
may be similar to the stress response seen in cells treated with chemotherapy or 
radiation.  
 
In our study there was a wide variation in the expression of basal total EGFR between 
cell lines as measured by qPCR. However, there was no correlation between total 
EGFR expression and sensitivity to reovirus oncolysis. For example, the DU145 cell 
line had comparatively high basal total EGFR expression but was relatively resistant 
to reovirus with an ED50 of MOI30. DU145 was also the cell line that showed the 
most consistent increase in phosphorylated EGFR expression on infection with 
reovirus. These findings are consistant with the work of Harrington et al. that show 
that in a panel of head and neck cell lines there was no correlation between basal total 
EGFR expression and reovirus sensitivity
188
. Furthermore, they actually found a 
negative correlation between basal phosphorylated EGFR expression and reovirus 
sensitivity, the reverse of the expected trend.  
 
To better understand the relationship between EGFR expression and reovirus 
oncolysis we attempted to knockdown EGFR using small interfering RNAs. This 
work was not completed optimally before the conclusion of my experimental work 
but initial experiments indicated that knocking down EGFR had no impact on the 
sensitivity to reovirus. However, manipulation of the DU145 cell line, which had 
shown the most striking increase in EGFR expression, proved difficult and requires 
more optimisation. The PC3 cell line was used as it had shown increased EGFR 
activation on reovirus infection and was easier to transfect successfully with siRNA. 
Despite this, further optimisation is required as at best only 40% of EGFR was 
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knocked-down in initial experiments and the manufacturers suggest at least 70% 
knockdown is required to obtain meaningful results.  
 
The lack of any change in reovirus sensitivity, albeit with suboptimal EGFR 
knockdown, complements findings by Harrington et al
188
. They assessed the effect of 
both stimulation with EGF, and EGFR blockade using an anti-EGFR antibody and an 
EGFR tyrosine kinase inhibitor, in head and neck cancer cell lines. Neither treatment 
altered the survival of cells treated with reovirus. They also showed that there was no 
effect of either stimulation or blockade on the level of reoviral replication by TCID50 
assay. These findings were seen in cells with high and low basal EGFR expression. 
Also, inhibition of signalling downstream of Ras was found to have no effect on 
reovirus oncolysis. 
 
To determine the effect of EGFR activation after reovirus infection, the knockdown 
experiments should be optimised with the DU145 cell line. Alternatively, EGFR 
could be blocked using a monoclonal antibody or tyrosine kinase receptor. If there 
was evidence of decreased cell survival after EGFR knockdown then the effect of 
reovirus infection on activated Ras and PKR levels could be assessed as well as the 
level of reoviral replication.  
 
Alternatively, the increased EGFR phosphorylation seen following infection with 
reovirus may constitute a pro-survival response as seen in cells exposed to 
chemotherapy
178,179,189,190
. It is thought that EGFR promotes cell survival and protects 
cells from Fas-induced apoptosis via activation of the Akt and MAPK pathways
191
. In 
these cell lines EGFR activation may be necessary for their survival following 
infection, but also make them more sensitive to EGFR inhibition. If this were the case 
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it raises the possibility of combining reovirus treatment with an EGFR antagonist to 
enhance tumour cell death. As described earlier, the combination of the chemotherapy 
agents oxaliplatin and 5FU with gefitinib was synergistic in cell lines where the 
addition of the chemotherapeutic agent led to an increase in phosphorylated EGFR 
levels
178
, and similar results were also seen with cisplatin in non-small cell lung 
cancer cells
192
. It should be noted however that the combination was antagonistic in 
cells where phosphorylated EGFR was decreased on addition of the chemotherapeutic 
agent, highlighting the cell specific nature of the interaction between agents. Without 
the data from the knockdown experiments it is difficult to make meaningful 
conclusions about the role of EGFR after reovirus infection and whether EGFR 
inhibition would be a potentially useful therapeutic target. 
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Chapter 5 
 
 
REO-10: 
A Phase 1 Study of intravenous Reovirus and 
Docetaxel in Patients with Advanced Cancer  
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5.1 Introduction 
Reovirus type 3 Dearing (Reolysin; Oncolytics Biotech), is a wild type double-
stranded RNA virus which is ubiquitous and non-pathogenic in humans
68
. It has been 
shown to be oncolytic by its ability to replicate selectively in transformed cells, but 
not in normal cells
72
. Activation of the Ras pathway in transformed cells, or their 
upstream or downstream elements, is an important factor in a cell’s permissiveness to 
reovirus oncolysis
193
. This is in part due to the inability of Ras-activated cells to 
phosphorylate cellular PKR, but also due to enhancement of virus uncoating, particle 
infectivity and apoptosis-dependent release
86
. Mutations that activate Ras itself, or 
elements in its pathway, are present in over 60% of cancers
75
. These cancers are 
therefore potential targets for reovirus oncolysis.  
 
A number of phase 1 studies have been undertaken to look at the safety of reovirus in 
patients with a range of advanced cancers
162
. Early trials focused on intralesional 
delivery of reovirus, which was found to be safe with evidence of response in both 
injected tumour and distant metastases
194
. Systemic delivery of reovirus has been 
shown to be safe and well tolerated, with objective evidence of response in a number 
of cases
107,109
. Notably no maximum tolerated dose was reached. Current trials have 
focused on the combination of systemic reovirus with cytotoxic chemotherapy.  
 
The taxane analogue docetaxel has efficacy in a wide range of tumour types 
commonly driven by activated Ras. It acts by disrupting the microtubular network in 
cells that is essential for mitotic and interphase cellular functions. In vitro and in vivo 
data suggests that the combination of docetaxel and reovirus is synergistic
94,195
. In 
addition to the exploitation of oncogene signalling, reovirus activates the host immune 
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response to potentially enhance antitumor responses through the efficient induction of 
type I interferons
196
. Also, the local inflammatory response generated by reovirus-
infected tumor cells causes bystander toxicity against reovirus-resistant tumor cells 
and activation of human myeloid dendritic cells
99
. This phase I dose escalation study 
was conducted across three centres in the United Kingdom. It was designed to 
determine the maximum tolerated dose (MTD) and any dose limiting toxicities 
(DLT). Secondary objectives included evaluation of the immune response to reovirus 
when given with docetaxel, analysis of the pharmacokinetics of docetaxel when given 
with reovirus, and assessment of any antitumour activity. 
 
5.2 Methods 
Described in Chapter 2. 
 
5.3 Results 
5.3.1 Patients 
A total of 25 patients were enrolled into the study across three centres between June 
2007 and January 2009. Their demographics are summarised in table 5.2. One patient 
failed to start treatment due to worsening liver function tests after enrolment, all 
others received at least one cycle. They were treated over three dose levels and 
received a total of 98 cycles (median 3; range 1-8), summarised in table 5.3. 16 
patients completed at least two cycles of treatment and were therefore eligible for 
response assessment. Tumour diagnosis and exposure to prior therapy is summarised 
in table 5.2. 
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Table 5.1   
 Patient Characteristics 
No. patients 
n=25 
 Gender 
         Male 
         Female 
 
21 
4 
 Age (years) 
         Median 
         Range 
 
60 
32-77 
 Previous chemo lines 
         0 
         1 
         2 
        >2 
 
2 
17 
4 
2 
 Cancer Diagnosis 
        Oesophagus 
        Prostate 
        Melanoma 
        Pancreas 
        Unknown 1° 
        Breast 
        Stomach 
        Mesothelioma 
        Hepatocellular 
        Bronchoalveolar  
 
6 
4 
4 
4 
2 
1 
1 
1 
1 
1 
 ECOG status 
         0 
         1 
         2 
 
5 
20 
0 
 
 
Table 5.2: Patients treated at each dose level and DLT observed 
Cohort No. of Patients 
Reolysin dose 
(TCID50) 
Total number 
of cycles 
(range) 
DLT Event 
1 4 3 x 10
9
 16 (1-6) - 
2 4 1 x 10
10
 20 (2-8) - 
3 16 3 x 10
10
 62 (1-8) G4 Neutropaenia 
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5.3.2 Safety and Toxicities 
The treatment was well tolerated with the most common side-effects being flu-like 
symptoms (fever, chills, and headache), diarrhoea, fatigue and neutropaenia. The 
grade 3-4 toxicities are given in table 5.4. There were a total of six grade 4 toxicities. 
This included four episodes of grade 4 neutropaenia in cohort 3 all of which were 
thought to be due to the docetaxel therapy alone. One man with prostate carcinoma 
and a rectovescical fistula had a dose limiting toxicity with grade 4 neutropaenia after 
his first cycle of treatment. He continued on the study on the cohort 2 dose of reovirus 
and a 20% reduction in docetaxel for a further 4 cycles without any further DLTs. 
One episode of grade 4 neutropaenia was complicated by sepsis though the patient 
fully recovered and completed eight cycles of treatment, the same patient developed 
grade 4 lymphopaenia during their treatment. All other toxicities were grade 3 or less. 
One patient with hepatocellular carcinoma developed a grade three rise in AST on day 
5 of cycle 1, thought to be due to disease progression, and treatment was withheld. 
Consequently, this patient was replaced in the cohort.  
 
Flu-like symptoms typically occurred 2-4 days after reovirus administration and were 
easily controlled with paracetamol and non-steroidal anti-inflammatory medication. 
Symptoms appeared to be more common in the first cycle of treatment and milder in 
subsequent cycles. The incidence of neutropaenia was not affected by the dose level 
of reovirus, however there was a relationship between neutropaenia and the amount of 
previous chemotherapy received, with all the patients who had grade 4 neutropaenia 
having received at least 6 cycles of chemotherapy before enrolment. 
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  Table 5.3 Grade 3 toxicities observed for each reovirus dose level (n=25) 
 Dose Level  
 1 2 3 Total 
(%) 
Number of patients 5 4 16 25 
Toxicity     
Neutropaenia 1 3 3 7 (28) 
Neutropaenia with fever   1 1 (4) 
Thrombocytopaenia   1 1 (4) 
Pancytopaenia   1 1 (4) 
Fatigue   1 1 (4) 
Vomiting 1  1 2 (8) 
Diarrhoea 1  1 2 (8) 
Abdominal pain   1 1 (4) 
Bowel obstruction   1 1 (4) 
Nausea   1 1 (4) 
Dehydration   1 1 (4) 
Gastric Bleed   1 1 (4) 
Tachycardia 1 1  2 (8) 
Abnormal ALP  1  1 (4) 
Perinanal abscess   1 1 (4) 
Pyrexia  1  1 (4) 
Hypotension   1 1 (4) 
Hypokalaemia   1 1 (4) 
Hypophosphataemia   1 1 (4) 
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Pre-treatment and post-treatment serum, urine, saliva and anal swabs were negative in 
all but two patients using RT-PCR screening based on 35 cycle amplification. In 
patient 0308, positive signal was detected in the serum on day 5 of cycle 1. Patient 
0317 had positive signal in the urine and saliva on day 15 of cycle 1, and also in the 
serum on day 5, and the anal swab on day 15 of cycle 2. This patient also had a 
positive reading in the pre-treatment serum sample which may indicate 
contamination. See figure 5.1. 
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Figure 5.1 RT-PCR analysis of viral shedding  
RT-PCR results from the first 2 cycles of serum, urine, saliva and anal swab for 
reovirus in two patients, 308 (top) and 317 (bottom). White arrows indicate row with 
reovirus RNA (300-bp PCR product). Pre denotes pretreatment; C denotes cycle; D 
denotes day. Symbols P,U,S,A denote plasma, urine, saliva and anal swab 
respectively. Data courtesy of Kevin Harrington 
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5.3.3 NARA Response 
22 patients had data available for analysis of the increase in neutralising antibody 
titres (NARA). This was expressed as the fold increase in antibody titre compared to 
pre-treatment. All patients showed an increase in NARA titres with a range of 27-
2187 (median 243) at day 15, cycle 1, and 27-6561 (median 729) at peak (Figure 5.2). 
From previous studies, evidence of effective immune modulation was taken if the day 
15, cycle 1 NARA showed only a 10-50 fold increase over the pre-treatment control. 
In this study, only one patient, 101, had evidence of immune modulation. However, 
this patient had a dramatic fall in his neutrophil and lymphocyte count after the 
second day of treatment and was consequently taken off study. All the other patients 
had increases in their NARA of 80-fold or more, and indicating that docetaxel has 
little effect on the production of neutralising antibodies to reovirus. 
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Figure 5.2 Fold increase in reoviral antibody titre 
Graph shows the fold increase in reoviral antibody titre over pre-treatment in the 22 
patients for whom data were available. Both the cycle 1, day 15 (white) and peak 
(grey) reoviral antibody titre are shown. Data courtesy of Victoria Roulstone 
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5.3.4 Response Assessment 
Sixteen patients were eligible for response assessment having completed 2 cycles of 
treatment (Table 5.5). Objective radiological responses were seen in 4 patients. There 
was one complete response in the liver of a patient with metastatic breast carcinoma 
(Figure 5.3). This patient completed eight cycles of treatment with no evidence of 
disease recurrence in the liver at the end of study. Three patients had objective 
evidence of a partial response: a patient with ocular melanoma had a 30% reduction in 
the size of their liver metastases, a patient with gastric carcinoma had a 32% reduction 
in the size of their target lymph node metastases, and a patient with gastro-
oesophageal carcinoma had a 32% reduction in their lung metastases. Ten patients 
had evidence of stable disease for at least 2 cycles, six of which completed at least six 
cycles of treatment. Three patients with radiologically stable disease had evidence of 
a minor response: a patient with mesothelioma, who received six cycles, had a 23% 
decrease in the size of a target mediastinal lymph node, a patient with a pancreatic 
carcinoma had a 48% decrease in their Ca19.9 tumour marker, and there was a 30% 
fall in PSA in a patient with prostate carcinoma. 
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Table 5.4 Antitumour activity in evaluable patients 
Best Response No. of Patients Tumour Types Reduction 
 
 
Partial Response 
 
 
 
 
4 
Breast 
 
Stomach 
 
Gastro-oesohageal 
 
Ocular Melanoma 
CR in liver; SD in 
bone 
↓32% in lymph nodes 
 
Minor response 
 
 
3 
 
Mesothelioma 
Prostate 
SCC H + N 
↓23% in lymph nodes 
↓30% in PSA 
↓26% in lymph node 
 
 
Stable Disease 
 
 
 
 
7 
Prostate 
Unknown 1° 
Melanoma 
Oesophagus 
Pancreas 
 
 
 
 
 
 
Figure 5.3 Complete response in liver 
CT scans of patient with metastatic breast carcinoma with liver metastases (black 
arrows), before treatment (left) and after six cycles of treatment (right), showing no 
evidence of residual disease. 
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5.3.5 Viral replication in tumour biopsies 
Where possible, fine needle core biopsies of accessible metastases were taken on day 
5, cycle 2 of treatment. Evaluable tissue was obtained from three patients: prostate 
cancer (iliac lymph node biopsy), unknown primary tumour (liver biopsy) and pleural 
mesothelioma (pleural biopsy) and immunohistochemistry for reovirus protein 
completed. Figure 5.4. Compared to control sections of normal human liver, reoviral 
protein expression was observed in tumour cells in all 3 biopsies. The staining was 
mainly cytoplasmic and the strongest expression seen in metastatic mesothelioma. 
 
No reovirus was detected using TCID50 assays in any of the samples. When the same 
samples were analysed using RT-PCR, with the same protocol as for the viral 
shedding assay, reovirus was detected, but only after 70 amplification cycles whereas 
no virus was detected after 35 cycles.  
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Figure 5.4 Expression of reoviral protein (red stain) in post treatment biopsies. 
A: normal liver (magnification x400); B: liver biopsy from metastasis from carcinoma 
unknown primary (x400); C: normal liver adjacent to liver metastasis from carcinoma 
unknown primary (x400); D; metastatic prostate cancer in an iliac lymph node (x200); 
E: Pleural biopsy malignant mesothelioma (x400). Large arrow is tumour, small 
arrow a fibroblast. Images courtesy of Gerard Nuovo. 
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5.3.6 Pharmacokinetics 
The effect of reovirus on docetaxel pharmacokinetics was assessed by the 
measurement of serial serum samples after intravenous delivery of docetaxel. All 
patients had similar results, with no difference in docetaxel clearance than would be 
expected in patients receiving docetaxel alone
197
. Peak concentration of docetaxel 
ranged from 1510-4080 ng/ml between 15 minutes and 30 minutes after docetaxel 
administration. The concentration of docetaxel fell below 100ng/ml within two hours 
in all patients. There was no correlation between docetaxel clearance and dose 
escalation of reovirus. See figure 5.6. 
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Figure 5.5 Clearance of Docetaxel 
Serum samples were collected at regular intervals after the administration of 
docetaxel. Data are representative of the first nine patients treated. 
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5.4 Discussion 
The purpose of this study was to determine the safety, DLT and MTD of intravenous 
reovirus in combination with docetaxel chemotherapy in patients with advanced solid 
malignancies. In keeping with experience with other viral therapies, it was always 
anticipated that the therapeutic potential of reovirus would be realised through 
combination with other anticancer agents. Supporting preclinical data suggested 
strong potential synergy between the two agents through enhanced tumour apoptosis. 
This study also allowed an evaluation of any immunomodulatory effects of docetaxel 
on the humoral response to reovirus, and also whether concurrent treatment with 
reovirus affected the pharmacokinetics and clearance of docetaxel.  
 
A number of chemotherapy/oncolytic virus combinations have been evaluated to date, 
and have been shown to result in marked antitumor effects without compromising 
safety. Onyx-015, an oncolytic adenovirus engineered to replicate in p53 mutant 
tumour cells, showed enhanced clinical efficacy when combined intratumorally with 
systemic cisplatin and 5- fluorouracil, compared to chemotherapy alone
48
. A large 
number of pre-clinical reports indicate marked synergy between oncolytic viruses, 
with varied mechanisms of action, and a range of chemotherapeutic agents
114,198-203
. 
Not surprisingly, the mechanisms underlying the observed synergies are incompletely 
understood.  
 
As a single agent, reovirus has been shown to be safe in human use, and associated 
with minimal toxicity when given intravenously or intratumorally in patients with a 
wide range of solid cancers
107,109
. The toxicities seen in this study included fever, flu-
like symptoms, fatigue and nausea, and were similar to what has been reported with 
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either agent alone. As only one DLT, of grade 4 neutropaenia, was encountered the 
MTD was not technically reached. However, the highest dose of reovirus available for 
administration is 3 x 10
10
 TCID50 and this combined with docetaxel 75mg/m
2
 is the 
recommended dose for ongoing studies. 
 
As in previous trials of single agent reovirus, viral shedding was observed 
infrequently (two patients). One had positive samples from the serum, saliva, urine 
and anal swab, while the other patient just had a positive serum sample. The results 
suggest that there is rapid clearance of the virus from the circulation which is 
unaffected by the administration of docetaxel. There was a rapid induction of a 
humoral response to reovirus with all patients showing an increase in the NARA titres 
after the first cycle. Despite its reported immunomodulatory effects
204
, docetaxel 
appeared to have no effect on the NARA response. From the single agent reovirus 
study by Vidal et al the median increase in NARA titres above baseline was 250-fold. 
They proposed that successful immune modulation could be defined as a rise in 
NARA titre that is at least 10-fold lower than observed in the single agent reovirus 
studies. Only one patient in this study met that criteria and he had an unusual and 
dramatic fall in his neutrophil and lymphocyte count on cycle 1, day 2 and was taken 
off study. It is possible that the reduced exposure to reovirus and myelosuppression 
may have limited the extent of the NARA response. 
The clearance of docetaxel was similar in all patients and across all cohorts with no 
obvious change with reovirus dose.  
 
While not a primary endpoint of the study, objective radiological tumour responses 
were seen. Given that all patients were docetaxel-naïve it is impossible to determine 
whether responses were as a result of either agent alone, or their combination. Only 
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two patients had not received prior chemotherapy, both had hormone refractory 
prostate cancer. The majority of patients had received one previous line of 
chemotherapy, though six patients had two or more lines of chemotherapy. Of note 
two patients had received prior paclitaxel chemotherapy. One of these with breast 
cancer and liver metastases completed 8 cycles of treatment on the study with a 
complete response in her liver. The other patient had carcinoma of unknown primary 
site and completed six cycles of treatment with stable disease. 
 
Partial responses were seen in three further patients with ocular melanoma, gastric 
carcinoma, and oesophageal cancer. All three completed at least six cycles of 
treatment. A further ten patients had stable disease as a best response and only two of 
the evaluable patients had disease progression after the first two cycles. Taken 
together this translates into a disease control rate of 88% and an objective response 
rate of 25%. While this response rate fits in with reported response rates for second 
line single agent docetaxel (melanoma 14%
205
; gastric 20%
206
; breast 30-50%
207
, the 
high disease control rate and response in two patients previously treated with a taxane 
is encouraging. In our previous study REO5, where reovirus was administered as a 
single agent, we were able to isolate and propagate reovirus from post-treatment 
tumour biopsy tissue. Although we were unable to demonstrate this in the current 
studies, in all three patients where post treatment tumour biopsies were taken, we 
found reoviral protein expression in tumour cells by immunohistochemistry as clear 
evidence of virus tracking to sites of metastases. The reovirus staining was mainly 
cytoplasmic and largely restricted to tumour cells with much lower expression in 
normal adjacent tissue (liver and fibroblasts). Furthermore, in one biopsy, we 
demonstrated co-localisation of replicating virus in microtubular protein consistent 
with proliferating virus in the tumour. 
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Reovirus as a single agent is safe and demonstrates modest efficacy. However, the 
future place of reovirus as an anticancer agent is likely to depend on strategies that 
improve systemic delivery to the tumour, avoid rapid viral clearance by the immune 
system, and combine reovirus with other anticancer agents. Here we present the first 
clinical trial of reovirus combined with a chemotherapeutic agent. The combination is 
safe and the recommended dose for future studies is 3 x 10
10
 TCID50 of reovirus and 
75mg/m
2
 of docetaxel. Disease stabilisation rates for this combination are promising 
and further studies are warranted. 
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Recent progress in the understanding of cancer cell biology has led to the 
development of a plethora of targeted agents. While this has strengthened the armoury 
at the disposal of clinicians and led to real improvements in patient outcomes, it is 
increasingly apparent that agents that block a single receptor or component of a 
signalling pathway are unlikely to have a definitive impact on a heterogeneous tumour 
containing a large number of different clones. In the case of monoclonal antibodies, 
combination with conventional cytotoxic treatments has led to impressive 
improvements in cancer cell death and tumour control. Other targeted agents have not 
shown such promise in combination with conventional treatments, either due to 
toxicity or lack of synergy. Consequently, new treatment strategies are urgently 
required.  
 
The renewed interest in virotherapy has led to the development of agents that could 
potentially overcome some of these hurdles. Oncolytic viruses are particularly 
attractive as they selectively target cancer cells reducing the likelihood of toxicity. 
Reovirus has shown considerable promise in the pre-clinical and clinical settings. 
While reovirus has been demonstrated to be safe when given intravenously, single 
agent response rates have been modest and the focus has turned to the combination 
with other agents. There has also been considerable effort to understand the 
mechanism of reovirus selectivity and mechanism of cell killing. We have presented 
data following 3 different lines of enquiry: what is the influence of EGFR expression 
on reovirus oncolysis, can targeting mTOR improve reovirus oncolysis, and can 
reovirus be combined safely with the conventional cytotoxic docetaxel to improve 
response? 
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It is clear that to optimise the potential of virotherapy, and reovirus in particular, we 
need to improve our understanding of the mechanism of tumour cell selectivity, 
permissiveness and oncolysis. Initial interest in reovirus focused on its apparent 
ability to replicate selectively in Ras transformed cells. This was demonstrated to be 
in part due to these cells inability to phosphorylate cellular PKR, however it is now 
clear that other mechanisms play a part. It has also been shown that virus uncoating, 
assembly, and apoptosis-dependent release is enhanced in Ras-transformed cells. To 
better understand the cellular changes occurring in cells exposed to reovirus we 
performed microarray on B16 melanoma cells before and after reovirus infection. We 
were intrigued by the finding of significant up-regulation of EGFR in cells exposed to 
reovirus as EGFR is an important component in the Ras pathway. We were unable to 
demonstrate a clear effect of knocking down EGFR on reovirus oncolysis, although 
the knockdown experiment had not been fully optimised. Data showing no effect of 
EGFR blockade in head and neck cell lines
188
 suggests that EGFR does not play an 
important role in reovirus oncolysis and the upregulation seen may be a stress 
response. However, it is also possible that this finding is cell line specific and further 
work on the B16 melanoma cells would be of interest. 
 
We looked at the combination of reovirus and the mTOR inhibitor rapamycin in the 
pre-clinical setting and found synergy both in vitro and in vivo. The in vitro 
experiments observed synergy that was sequence dependent but this was not seen in 
vivo. As with other investigators studying virus combination treatment, we were 
unable to determine a mechanism for this synergy. However, we were able to 
demonstrate that the enhanced tumour cell kill was not due to suppression of the 
antibody response as might have been expected given rapamycin is known to be 
immunosuppressive. Interestingly, we did demonstrate clear antagonism when 
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rapamycin was given concomitantly or prior to reovirus, with shut down of viral 
production. But in vivo the effect of sequence was lost and the combination was better 
than either agent alone. Other mechanisms for synergy postulated include a direct 
effect of Akt/mTOR signalling on viral oncolysis, reduction in inhibitory interferon, 
and changes to tumour vasculature caused by rapamycin leading to viral trapping 
within the tumour. We were unable to explore all the possible mechanisms and further 
research is required to better understand the interaction between reovirus and 
rapamycin. 
 
We have presented here the results of a phase 1 study combinating reovirus with 
docetaxel. This confirmed that the administration of intravenous reovirus was safe in 
conjunction with the cytotoxic agent docetaxel, with no maximum tolerated dose 
reached. Activity was demonstrated and reovirus was isolated from tumours. This 
phase 1 study was one of three that assessed the safety of combining iv reovirus with 
conventional cytotoxic agents, the others being gemcitabine and the doublet of 
carboplatin and paclitaxel. All have now been published and show that the 
combination of reovirus with these cytotoxic agents is safe. A grade 3 rise in liver 
enzymes was seen in the gemcitabine study though this was likely to be due to the co-
administration of paracetamol which is know to interact with serotype 1 reovirus
208
. 
 
The addition of docetaxel did not appear to attenuate the neutralising antireovirus 
antibody (NARA) response. However, with both gemcitabine, and carboplatin and 
paclitaxel, there appeared to be a delay in the induction and peak levels reached. It 
should be stated that this was compared to previous studies using single agent iv 
reovirus and are therefore not directly comparable. What was apparent from all three 
studies was even if there was some attenuation of the antibody response, there is still a 
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rapid development of antireoviral antibodies and clearance of reovirus after 
intravenous delivery. The results of a further phase 1 trial that specifically aims to 
attenuate the NARA response have not yet been published. 
 
 The combination of carboplatin and paclitaxel with reovirus appeared to show the 
most promise, with responses seen in patients with advanced disease many of whom 
had already had prior exposure to a platinum agent. Consequently, a phase 3 trial is 
now being recruited to compare the combination of carboplatin and paclitaxel with or 
without reovirus. It will be fascinating to see whether the synergy seen in preclinical 
models can be replicated in the clinical setting. 
 
A recent study has shown that the status of p53 affects the efficacy of reovirus 
combination therapy
209
. Using sublethal doses of three cytotoxic chemotherapy agents 
in combination with reovirus, they found that apoptosis was enhanced in a p53-
dependent manner with two of the three drugs. They concluded that choosing the right 
chemotherapeutic agent to combine with reovirus had the potential to enhance 
reovirus-induced cancer cell death and reduce side effects. This approach is different 
from our phase 1 trial as only sublethal doses of chemotherapy drug were used, but 
does share something in common with the REO-12 trial which used low dose 
cyclophosphamide in an attempt to abrogate the neutralising antibody response. The 
effect on p53 was not assessed in the pre-clinical study and we are still awaiting 
results of the phase 1 trial of this combination.  
 
Scheduling of the combination drug may also be of importance. We demonstrated 
sequence-dependent synergy in vitro with the combination of reovirus and rapamycin 
though this was not replicated in vivo. Kottke et al. have shown that increases in 
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vascular endothelial growth factor (VEGF) signalling to tumour-associated 
endothelial cells induces a pro-viral state, allowing growth of reovirus in the tumour 
endothelium and consequent cell death and collapse of the tumour vasculature
210
. By 
careful scheduling of paclitaxel, to induce VEGF signalling, prior to systemic delivery 
of reovirus, the group were able to demonstrate tumour regression in vivo despite both 
agents having minimal individual activity
211
. 
 
Other groups have tried to modify reovirus to enhance its oncolytic ability while 
maintaining its selectivity for cancer cells. One such study used classical genetics to 
isolate two variants with better replication in human tumour cell lines compared to 
wild type
212
. These variants had a mutation in L2 and S1 viral proteins respectively, 
which led to enhanced virion infectivity and superior oncolysis. When tested in a 
mouse melanoma model, similar to ours, prolonged survival was demonstrated in 
mice receiving variant reovirus compared to wild type. 
 
While the adaptive immune system is clearly a major obstacle for the delivery of 
reovirus to tumours, it is also apparent that the cellular immune system plays a central 
role in mediating anti-tumour activity. Indeed, as discussed earlier, the efficacy of 
reovirus is dependent on an adequate immune response. The resolution of these two 
potentially conflicting immune responses and their effect on viral delivery and local 
efficacy is one of the main challenges to be addressed if reovirus is to make a 
contribution to cancer treatment. To date the clinical use of other oncolytic viruses has 
been via direct tumoural administration. H101, an adenovirus, is licensed for use in 
China for local treatment of head and neck cancers. T-Vec, an engineered herpes 
virus, has been tested in a phase 2 trial where all accessible lesions of patients with 
malignant melanoma were injected intratumourally
213
. The results of a phase 3 trial 
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are now awaited. Numerous viruses have been injected into the tumour bed of 
resected gliomas and the intraperitoneal route has been used in patients with ovarian 
cancer. While activity is seen, intratumoural delivery is not possible for many tumours 
and is invasive for patients.  
 
A number of strategies have been adopted to try and improve systemic delivery of 
oncolytic viruses to tumours. These include changing the viral coat, using lipid 
encapsulation or polymer coating, though so far these techniques remain technically 
challenging
32,214
. Another approach has been the use of cell carriers to chaperone viral 
particles within the circulation. Though this technique has been applied to other 
oncolytic viruses, there has been considerable research using reovirus. Dendritic cells 
have been shown to deliver reovirus for melanoma cell killing in vitro, despite the 
presence of neutralising antibodies
215
. Importantly, these dendritic cells were able to 
prime specific antitumour responses. This has since been tested in the clinical 
setting
216
. In this study patients received intravenous reovirus before surgical removal 
of colorectal liver metastases. Reovirus was isolated from tumour cells but not from 
normal hepatocytes despite all patients having prior exposure to reovirus. Replication 
competent reovirus was retrieved from circulating mononuclear cells but not from the 
serum. This confirms that reovirus does appear to ‘hitchike’ to tumours using immune 
cells. Further optimisation of this phenomenon may overcome one of the major 
barriers to the clinical use of reovirus. 
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Future Work 
 
The data presented represents the work of two years. Inevitably certain experiments 
were not optimised and lines of enquiry not completed. We found synergy both in 
vitro and in vivo using the novel combination of reovirus and rapamycin. However, 
we were not able to determine a mechanism for this synergy. It would be interesting 
to pursue this further with particular focus on the effect of mTOR inhibition on the 
immune response to reovirus infection. This would include more detailed analysis of 
the neutralising antibody response and also the effect on cytokine production. Given 
the fine interplay described so far between oncolytic viruses and the host immune 
system more in vivo data regarding the specific combination of reovirus and 
rapamycin (and other more clinically relevant mTOR inhibitors) would be useful. We 
also looked at the effect of the reovirus and rapamycin combination on cell signalling, 
particularly any effect on the Ras and PI3K pathways. Unfortunately, this data was 
not adequate at the time of completion but it would be useful to know whether the 
combination of agents led to any unusual changes in cell signalling pathways. I did 
not manage to optimise the EGFR shutdown experiments, and while this would be 
interesting to complete, from the work done both other groups discussed in chapter 3 
it seems unlikely that EGFR inhibition will prove a useful strategy to improve 
reovirus oncolysis.  
  
Numerous phase I clinic trials have now been completed assessing the combination of 
reovirus with standard anti-cancer therapeutic agents. While all have shown that the 
combination is safe, there has so far been no phase III randomised controlled-trial data 
comparing standard cytotoxic chemotherapy with or without reovirus. The most 
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promising combination in phase I trials (assessing carboplatin and paclitaxel with 
reovirus in patients with head and neck cancers) has been rolled out in a phase III trial 
but the results are still awaited. Clearly, if the results are positive then this would 
represent a significant advance for oncolytic virotherapy. However, it is likely that the 
benefits of combination treatment will be modest and there will be a need to look for 
more efficacious combinations.  
 
Recent published work assessing the oncolytic potential of reovirus has focused on 
the ability of the virus to prime the immune system. While a number of groups have 
assessed the combination of oncolytic viruses with newer small molecules, there are 
two areas that it would be interesting to explore further in relation to reovirus. Firstly, 
the scheduling of reovirus and the combination agent, which has not been look at in 
the clinical setting. Secondly, the use of the newer immune-modulatory drugs such as 
the checkpoint inhibitor ipilimumab.  
 
We presented in vitro data showing a difference in the degree of cell death when 
rapamycin was given before or after reovirus. While this was not replicated in the in 
vivo setting other groups have also shown that sequencing of agents is important 
whether because of their effect on the cell cycle, immune response, or tumour 
vasculature. Given the balance described between immune priming and anti-viral 
response it is likely that drug/virus scheduling will be important. 
 
Checkpoint inhibitors, such as ipilimumab that target CTLA-4 inhibition of T cell 
responses, look like potentially promising agents to combine with oncolytic viruses. 
The combination of ipilimumab with Newcastle disease virus in a mouse melanoma 
model similar to the one we used led to a remarkable 70% tumour clearance rate 
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despite there being no response with either agent alone
217
. Importantly, the 
combination led to an increase in CD4+ and CD8+ cells and a reduction in T reg cells. 
The combination is not without risks however and it is not clear if the intravenous 
delivery of reovirus would be safe. 
 
 
 
Oncolytic viruses have shown potential as anticancer agents. The numerous 
preclinical studies undertaken have increased our understanding of viral oncolysis and 
helped the design of clinical trials. Reovirus is an archetypal oncolytic virus, with 
recent clinical trials, including the one presented here, demonstrating tumour 
responses and confirming that intravenous delivery is safe. The next line of research 
will be to try and improve viral delivery and enhance tumour response. 
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